FDA Calendar
Biotech Catalyst and FDA Calendar for your biotech stock investing. Use our tools on your road to profit in the stock market. Biotech stocks with key binary events/catalysts - FDA Approval/PDUFA, Advisory Committee and Phase 2 & 3 trial data releases dates.
Refer to the Biotech Historical Catalyst Calendar for completed biotech catalysts.
The catalyst date is the LATEST expected date for the catalyst to occur by. For example, if the catalyst date is 12/31/17, the event is expected to occur BY 12/31/17. It does NOT necessarily mean that the catalyst will occur ON this date. In most cases it will occur BEFORE.
Please refer to the "FDA Calendar Glossary" for a list of terms used in the FDA Decision Calendar.
LARGE CAP CATALYSTS - generally only Phase 3 catalysts noted in company presentations and/or earnings releases are shown.
PDUFA DATES - biosimilars and sNDA/sBLA filings and resubmissions are only noted if a PDUFA date has been released by the company. No official PDUFA date = No entry (e.g. Saxagliptin and dapagliflozin resubmission). Standard reviews for NDA/BLA filings use a 10 month estimate following filing acceptance for a NEW MOLECULAR ENTITY if no PDUFA date has been announced.
Pipeline data are current and updated daily! Click on the date for the source of the catalyst.
Financial data are updated each evening.
Subscribe HERE to ensure you receive your weekly FREE copy of the BioPharmCatalyst Biotech Stock Watch list and/or our daily option of Biotech Stock Price Movers and Pipeline Database updates.
Showing 558 drugs
| Ticker | Price | Drug | Stage | Catalyst |
|---|---|---|---|---|
| STML |
$8.50
+0.15 (+1.8%)
|
SL-401
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) cancer
|
Phase 2 |
Phase 2 enrollment completed - noted March 23, 2017. Update on patients enrolled in Stages 1 and 2 due at EHA June 23, 2017 with top-line data from Stage 3 due 2H 2017.
|
| AGIO |
$57.42
+0.64 (+1.12%)
|
AG-348
Pyruvate kinase deficiency
|
Phase 2 |
Phase 2 first data released at EHA meeting June 2016. Updated data due at EHA June 24, 2017 with further data due 2H 2017.
|
| GBT |
$29.25
-1.5 (-4.88%)
|
GBT440
Sickle cell disease in adolescents
|
Phase 1/2 |
Phase 2a initiated June 2016. Preliminary data due at European Hematology Association (EHA) - June 24, 2017.
|
| PTLA |
$38.25
-1.24 (-3.14%)
|
Betrixaban (The APEX Study)
Venous thromboembolism (VTE) Prevention
|
PDUFA priority review |
PDUFA date under priority review June 24, 2017. Phase 3 data released March 2016 did not meet primary endpoint.
|
| BLUE |
$118.50
-1.8 (-1.5%)
|
LentiGlobin - HGB-207 Northstar-2
non-β0/β0 transfusion-dependent thalassemia (TDT)
|
Phase 3 |
Noted on December 14, 2016 that Phase 3 dosing has commenced. Early data due at EHA June 25, 2017.
|
| ALNY |
$83.96
-0.57 (-0.66%)
|
Givosiran
Acute hepatic porphyrias
|
Phase 1 |
Phase 1 additional data to be presented June 26, 2017 at the International Congress on Porphyrins and Porphyrias (ICPP) with a Phase 3 trial to be initiated in late 2017.
|
| RARX |
$23.00
+0.42 (+1.86%)
|
RA101495
Paroxysmal nocturnal hemoglobinuria (PNH)
|
Phase 2 |
Phase 2 initiation of dosing announced April 26, 2017. Initial data due June 27, 2017.
|
| ACHN |
$4.30
+0.07 (+1.65%)
|
ACH-4471
Paroxysmal nocturnal hemoglobinuria (PNH)
|
Phase 2 |
Phase 2 initiation announced April 6, 2017. Interim data due 2Q 2017.
|
| ALDR |
$19.40
+0.4 (+2.11%)
|
ALD403 - PROMISE 1
Frequent episodic migraine
|
Phase 3 |
Phase 3 PROMISE 1 topline data due 2Q 2017.
|
| BTX |
$3.15
+0.17 (+5.7%)
|
OpRegen
Dry age-related macular degeneration (AMD)
|
Phase 1/2 |
Phase 2 second cohort underway. Interim data presented at May 8, 2017 at ARVO conference. Third cohort enrollment pending DSMB review due 2Q 2017.
|
| CARA |
$19.88
+0.38 (+1.95%)
|
CR845
Osteoarthritis (OA)
|
Phase 2b |
Phase 2b trial initiated September, 2016. Data are due 2Q 2017.
|
| CYTR |
$0.69
+0.02 (+4.34%)
|
Aldoxorubicin
Relapsed/refractory small cell lung cancer
|
Phase 2b |
Phase 2b data due 2Q 2017.
|
| GEMP |
$11.30
-0.02 (-0.18%)
|
Gemcabene - COBALT-1
Homozygous Familial Hypercholesterolemia (HoFH)
|
Phase 2b |
Phase 2b data due June 2017.
|
| GTXI |
$4.58
+0.28 (+6.51%)
|
Enobosarm
Breast cancer - advanced AR+ TNBC
|
Phase 2 |
Phase 2 prelim data from Stage 1 portion of trial due 2Q 2017.
|
| MTNB |
$2.52
-0.18 (-6.67%)
|
MAT2203
Vulvovaginal candidiasis (VVC)
|
Phase 2 |
Phase 2 top-line data due June 2017.
|
| NEOT |
$2.27
+0.08 (+3.84%)
|
LIPO-202
Reduction of localized fat deposits under the chin (submental fat)
|
Phase 2 |
Phase 3 endpoints not met December 2015. Phase 2 trial initiated December 23, 2016 with data due June 2017.
|
| PBYI |
$86.45
+6.2 (+7.73%)
|
Neratinib
Third-line HER2-positive metastatic breast cancer
|
Phase 3 |
Phase 3 data due 2Q 2017.
|
| VRX |
$15.50
+1.82 (+13.3%)
|
SAN-300
Rheumatoid Arthritis
|
Phase 2 |
Phase 2 data due 1H 2017.
|
| QURE |
$5.88
+0.56 (+10.53%)
|
AMT-060
hemophilia B
|
Phase 1/2 |
Phase 1/2 long term updated data to be presented at International Society of Thrombosis and Hemostasis (ISTH) meeting, July 8-13, 2017. Pivotal trial to be initiated in 2018. Exact date TBC.
|
| BMRN |
$97.06
-1.76 (-1.78%)
|
BMN 270
Hemophilia A
|
Phase 1/2 |
Phase 1/2 update due at International Society of Thrombosis and Haemostasis (ISTH) 2017 Congress, July 11, 2017. Phase 2b trial to be initiated 3Q 2017.
|
| NVS |
$86.34
+3.78 (+4.58%)
|
CTL019
Relapsed/Refractory B-Cell Acute lymphoblastic leukemia
|
PDUFA priority review |
PDUFA date under priority review announced March 29, 2017. No date given. Assume 6-month review - September 29, 2017. Advisory Committee Meeting July 12, 2017.
|
| PRTK |
$24.10
+0.55 (+2.34%)
|
Omadacycline - oral
Acute bacterial skin and skin structure infections (ABSSSI)
|
Phase 3 |
Phase 3 completion of enrollment announced May 8, 2017. Data due mid-July 2017. July 15 estimate based on company guidance of "mid-July".
|
| AMGN |
$173.82
+2.47 (+1.44%)
|
EVENITY (Romosozumab)
Osteoporosis
|
PDUFA |
PDUFA date July 19, 2017. However, likely to be delayed due to safety data from ARCH trial released May 22, 2017.
|
| OCUL |
$11.54
+0.5 (+4.53%)
|
DEXTENZA
Ocular inflammation and pain following cataract surgery
|
PDUFA |
CRL July 25 2016 - due to manufacturing deficiencies. NDA resubmitted, PDUFA date July 19, 2017.
|
| PBYI |
$86.45
+6.2 (+7.73%)
|
PB272 ExteNET trial
Extended adjuvant HER2-positive early stage breast cancer
|
PDUFA |
NDA filing announced July 21, 2016. Announced acceptance of NDA Filing September 20, 2016. PDUFA estimate July 21, 2017. Advisory Committee Meeting May 24, 2017 voted 12-4 in favor of recommending approval.
|
| EGRX |
$81.02
+0.24 (+0.3%)
|
Ryanodex
Exertional heat stroke (EHS)
|
PDUFA priority review |
PDUFA date under priority review July 23, 2017.
|
| GSK |
$44.16
+0.54 (+1.24%)
|
Benlysta (belimumab) - subcutaneous
Systemic lupus erythematosus (SLE)
|
PDUFA |
BLA filing announced September 23, 2016. PDUFA estimate July 23, 2017.
|
| DVAX |
$9.70
+0.35 (+3.74%)
|
HEPLISAV-B
Hepatitis B
|
PDUFA |
CRL February 25, 2013 and November 14, 2016. New PDUFA August 10, 2017. Advisory Committee Meeting July 28, 2017.
|
| ACRX |
$2.40
-0.1 (-4%)
|
Zalviso
Post-operative pain following open abdominal surgery and hip or knee replacement surgery
|
Phase 3 |
CRL Jul 26 2014. Additional clinical trial required. Phase 3 trial initiated September 2016. Data due mid-2017.
|
| ALKS |
$58.68
+1.02 (+1.77%)
|
ALKS 3831 - ENLIGHTEN-1
Schizophrenia
|
Phase 3 |
Pivotal trial initiated December 2015. Completion of enrollment announced May 1, 2017. Data due mid-2017.
|
| ALNY |
$83.96
-0.57 (-0.66%)
|
Patisiran APOLLO
Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR
|
Phase 3 |
Phase 3 data due mid-2017.
|
| ARNA |
$16.19
-0.41 (-2.48%)
|
Ralinepag
Pulmonary Arterial Hypertension
|
Phase 2 |
Phase 2 data due July 2017.
|
| AVEO |
$0.73
+0.02 (+4.01%)
|
TIVO-3 - tivozanib
Third line treatment of patients with renal cell cancer
|
Phase 3 |
Phase 3 completion of enrollment noted June 20, 2017. Futility analysis due mid-2017. Top-line data due 1Q 2018.
|
| AZN |
$35.36
+0.48 (+1.38%)
|
Durvalumab +/- tremelimumab (MYSTIC)
Lung cancer
|
Phase 3 |
Phase 3 PFS data mid-2017.
|
| AZN |
$35.36
+0.48 (+1.38%)
|
Acalabrutinib - ACE-LY-004
Relapsed or Refractory Mantle Cell Lymphoma
|
Phase 2 |
Phase 2 data 2Q or mid 2017.
|
| BIIB |
$280.57
+1.97 (+0.71%)
|
XLRS Gene Therapy
X-linked retinoschisis (XLRS)
|
Phase 1/2 |
Phase 1/2 data due mid-2017.
|
| BLPH |
$1.37
-0.02 (-1.44%)
|
INOpulse delivery device
Pulmonary Hypertension associated with COPD (PH-COPD)
|
Phase 2 |
Phase 2 initiated 3Q 2016. Data due mid-2017.
|
| CYTX |
$1.04
+0.03 (+2.97%)
|
ECCS-50
Scleroderma
|
Phase 3 |
Data are due early 3Q 2017. BPC estimate end of July as latest likely date.
|
| FATE |
$3.19
+0.01 (+0.31%)
|
ProHema - PROTECT
Acute graft-versus-host disease (GvHD) undergoing hematopoietic cell transplantation (HCT)
|
Phase 1/2 |
Phase 1/2 enrollment commenced December 2016. Safety data due mid-2017.
|
| FBIO |
$4.82
+0.03 (+0.63%)
|
CAEL‐101
AL amyloidosis
|
Phase 1/2 |
Phase 1/2 preliminary data due mid-2017 with full data due by the end of the year.
|
| GNCA |
$5.39
+0.12 (+2.27%)
|
GEN-003
Genital herpes
|
Phase 2b |
Phase 2b data released January 6, 2017. 12-month data due mid-2017. Phase 3 to commence 4Q 2017.
|
| ICPT |
$130.57
+2.17 (+1.69%)
|
Obeticholic acid (OCA) - CONTROL
NASH patients taking statins
|
Phase 2 |
Phase 2 data due mid-2017. Phase 3 trial to be initiated 2H 2017.
|
| ICPT |
$130.57
+2.17 (+1.69%)
|
Obeticholic acid (OCA) AESOP
Primary Sclerosing Cholangitis (PSC)
|
Phase 2 |
Phase 2 data due mid-2017.
|
| IRWD |
$19.61
+0.17 (+0.87%)
|
IW-3718
Gastroesophageal reflux disease (GERD)
|
Phase 2b |
Phase 2b data due mid-2017.
|
| ITEK |
$1.90
+0.07 (+4.11%)
|
Trabodenoson and latanoprost
Glaucoma
|
Phase 2 |
Phase 2 recruitment completed - noted April 11, 2017. Data due July 2017.
|
| KMDA |
$6.30
-1.2 (-16%)
|
Alpha-1 Antitrypsin (AAT)
Pediatric patients newly diagnosed with type 1 diabetes
|
Phase 2/3 |
Phase 2/3 data due mid-2017.
|
| KPTI |
$9.96
+0.46 (+4.84%)
|
Selinexor - SEAL
Dedifferentiated liposarcoma
|
Phase 2/3 |
Phase 2/3 trial initiated January 2016. Top-line data for the Phase 2 portion due mid-2017.
|
| MDWD |
$7.80
+0.15 (+1.96%)
|
EscharEx
Chronic and other hard-to-heal wounds
|
Phase 2 |
Phase 2 data released early February 2016. Primary endpoint met. Secondary endpoint of time to complete debridement not met. Top-line data from second cohort due mid-2017. Pivotal trial planned.
|
| MEIP |
$2.16
+0.03 (+1.41%)
|
ME-401
Chronic lymphocytic leukemia/small lymphocytic lymphoma or follicular lymphoma
|
Phase 1b |
Phase 1b data due mid-2017.
|
| MRK |
$66.02
+0.56 (+0.86%)
|
Anacetrapib (MK-0859)
Raising HDL-C and reducing LDL-C
|
Phase 3 |
Phase 3 data due mid-2017.
|
| MRNS |
$1.36
-0.05 (-3.55%)
|
Ganaxolone
CDKL5 disorder
|
Phase 2 |
Phase 2 preliminary CDKL5 cohort data released January 23, 2017. Top-line data due mid-2017.
|
| MRTX |
$4.05
+0.2 (+5.19%)
|
Mocetinostat and durvalumab
Non-small cell lung cancer (NSCLC)
|
Phase 2 |
Phase 2 combination trial initiated June 2016. Update due mid-2017.
|
| RDHL |
$8.96
-0.18 (-1.97%)
|
RHB-104 MAP US
Crohn’s disease
|
Phase 3 |
Phase 3 DSMB safety analysis released December 13, 2016 - trial to continue as planned. Interim efficacy analysis due mid-2017.
|
| RDUS |
$46.45
+2.2 (+4.97%)
|
Elacestrant (RAD1901)
Vasomotor symptoms
|
Phase 2b |
Phase 2b data due mid-2017.
|
| SNY |
$49.61
+1.01 (+2.08%)
|
Patisiran APOLLO
Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR
|
Phase 3 |
Phase 3 top-line data due mid-2017.
|
| SNY |
$49.61
+1.01 (+2.08%)
|
Sotagliflozin
Type 1 Diabetes
|
Phase 3 |
Phase 3 data released September 9, 2016 met primary endpoint. Data from second trial released December 21, 2016 - primary endpoint met. Data from third trial due mid-2017.
|
| TBPH |
$42.56
+1.84 (+4.51%)
|
Revefenacin
COPD
|
Phase 3 |
Phase 3 trials met primary endpoint. 12 month safety trial data (mid-2017) and NDA filing end of 2017.
|
| TBPH |
$42.56
+1.84 (+4.51%)
|
Velusetrag (TD-5108)
Gastroparesis
|
Phase 2b |
Phase 2b initiated mid March 2015. Completion of study due mid-2017.
|
| TGTX |
$12.00
+0.55 (+4.8%)
|
TG-1101 and TGR-1202 - UNITY-DLBCL study
Diffuse large B-cell lymphoma (DLBCL) cancer
|
Phase 2b |
Phase 2b enrollment commenced June 2016. First interim analysis due mid-2017.
|
| VKTX |
$1.04
+0.06 (+6.04%)
|
VK5211
Acute Hip Fracture
|
Phase 2 |
Phase 2 data due late summer 2017.
|
| VNDA |
$16.10
+0.3 (+1.9%)
|
VLY-686 (tradipitant)
Chronic pruritus in patients with atopic dermatitis
|
Phase 2 |
Phase 2 data due in mid-2017.
|
| VSTM |
$2.38
+0.08 (+3.48%)
|
Duvelisib - DUO
Cancer - relapsed/refractory chronic lymphocytic leukemia (CLL)
|
Phase 3 |
Phase 3 data due mid-2017.
|
| WINT |
$0.90
-0.01 (-1.11%)
|
Aerosurf
Respiratory Distress Syndrome - premature infants 26 to 32 weeks
|
Phase 2b |
Phase 2b interim safety review completed April 11, 2017. Trial to continue to completion. Top-line data due July 2017.
|
| WINT |
$0.90
-0.01 (-1.11%)
|
Aerosurf
Respiratory Distress Syndrome - premature infants 26 to 28 weeks
|
Phase 2a |
Phase 2a top-line data due July 2017.
|
| XENE |
$4.05
+0.05 (+1.25%)
|
TV-45070
Postherpetic neuralgia
|
Phase 2b |
Phase 2b initiated late March 2015. Data due mid-2017.
|
| ABBV |
$73.18
+1.84 (+2.58%)
|
Glecaprevir/Pibrentasvir (G/P)
Hepatitis C virus (HCV)
|
PDUFA priority review |
Priority review granted February 2, 2017. No PDUFA date supplied. Estimate August 2, 2017.
|
| BMY |
$57.33
+1.26 (+2.25%)
|
CM-142 – Opdivo
(dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC)
|
PDUFA priority review |
PDUFA date under priority review August 2, 2017.
|
| BMY |
$57.33
+1.26 (+2.25%)
|
CM-142 – Opdivo
(dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC)
|
PDUFA priority review |
PDUFA date under priority review August 2, 2017.
|
| BMY |
$57.33
+1.26 (+2.25%)
|
CM-142 – Opdivo
(dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC)
|
PDUFA priority review |
PDUFA date under priority review August 2, 2017.
|
| ENTA |
$37.11
+1.77 (+5.01%)
|
Glecaprevir/Pibrentasvir (G/P)
Hepatitis C virus (HCV)
|
PDUFA priority review |
Priority review granted February 2, 2017. No PDUFA date supplied. Estimate August 2, 2017.
|
| NVAX |
$1.19
+0.03 (+2.59%)
|
RSV F Vaccine immunogenicity trial
Respiratory Syncytial Virus (RSV) in older adults
|
Phase 2 |
Phase 2 trial initiation announced January 19, 2017. Data due by early August, 2017 (official guidance is within 90 days of May 8, 2017.
|
| AMGN |
$173.82
+2.47 (+1.44%)
|
BLINCYTO
Ph+ R/R ALL
|
PDUFA priority review |
PDUFA date under priority review August 14, 2017.
|
| ALNY |
$83.96
-0.57 (-0.66%)
|
ALN-HBV
Chronic hepatitis B virus (HBV)
|
Phase 1/2 |
Phase 1/2 trial initiated July 2016. Data are due mid 2017
|
| PFE |
$34.06
+0.18 (+0.53%)
|
Inotuzumab Ozogamicin
Relapsed or Refractory Acute Lymphoblastic Leukemia in Adults
|
PDUFA priority review |
Priority review announced February 21, 2016. Estimate PDUFA date August 21, 2017 at latest. Possibly earlier as NDA acceptance was announced following 3-day weekend.
|
| ADMS |
$16.82
-0.26 (-1.52%)
|
ADS-5102
Levodopa-Induced Dyskinesia
|
PDUFA |
PDUFA date August 24, 2017.
|
| VRX |
$15.50
+1.82 (+13.3%)
|
Latanoprostene bunod
Open angle glaucoma (OAG) or ocular hypertension (OHT)
|
PDUFA |
PDUFA date August 24, 2017 (resubmission)
|
| NVO |
$43.67
-0.04 (-0.09%)
|
Victoza (liraglutide)
Type 2 diabetes
|
PDUFA |
FDA Advisory Committee voted 17-2 vote from that Victoza provides substantial evidence of cardiovascular risk reduction. PDUFA date. sNDA filing announced October 25, 2017 - 10 month timeline would render a PDUFA date of on or about August 25, 2017.
|
| KMDA |
$6.30
-1.2 (-16%)
|
KamRAB
Prophylaxis of rabies disease
|
PDUFA |
PDUFA date August 29, 2017.
|
| AGIO |
$57.42
+0.64 (+1.12%)
|
Enasidenib (AG-221)
Advanced hematologic malignancies with an IDH2 mutation
|
PDUFA priority review |
PDUFA date August 30, 2017 under priority review.
|
| CELG |
$133.68
+0.85 (+0.64%)
|
Enasidenib (AG-221)
Relapsed/Refractory IDH2 mutant-positive Acute Myeloid Leukemia -
|
PDUFA priority review |
PDUFA date August 30, 2017 under priority review.
|
| ABBV |
$73.18
+1.84 (+2.58%)
|
ABT-494 - SELECT-BEYOND
Rheumatoid arthritis
|
Phase 3 |
Phase 3 top-line data due summer 2017. Estimate Aug 31 is last possible date.
|
| ABIO |
$2.45
+0 (+0%)
|
Gencaro - GENETIC-AF trial
Chronic Heart Failure
|
Phase 2b |
Phase 2b interim analysis due August 2017.
|
| ONCE |
$62.59
-1.88 (-2.92%)
|
SPK-8011
Hemophilia A
|
Phase 1/2 |
Phase 1/2 trial initial data due July or August 2017.
|
| ZYNE |
$7.30
+0 (+0%)
|
ZYN002 - STOP
Osteoarthritis
|
Phase 2 |
Phase 2 initiated September 2016. Data are due July or August 2017 (following epilepsy data).
|
| ZYNE |
$7.30
+0 (+0%)
|
ZYN002 - STAR 1
Adult Epilepsy Patients with Refractory Focal Seizures
|
Phase 2 |
Phase 2 dosing commenced August 2016. Data are due July or August 2017.
|
| ABBV |
$73.18
+1.84 (+2.58%)
|
Imbruvica
Second-line Chronic graft-versus-host disease (GVHD)
|
PDUFA priority review |
sNDA filing announced April 4, 2017. Assuming priority review would render a PDUFA date of September 4, 2017. Awaiting confirmation of official PDUFA date.
|
| AGN |
$247.11
+2.72 (+1.11%)
|
Liletta
Prevention of pregnancy
|
PDUFA |
sNDA accepted January 4, 2017. PDUFA estimate September 4, 2017.
|
| MYL |
$39.01
+0.74 (+1.93%)
|
MYL-1401O
Trastuzumab biosimilar
|
PDUFA |
PDUFA date September 7, 2017.
|
| FPRX |
$31.46
-0.18 (-0.57%)
|
FP-1039
Mesothelioma cancer
|
Phase 1b |
Phase 1b NSCLC halted, mesothelioma to continue. Data due at ESMO 8-12 September 2017. Exact date TBC.
|
| GTXI |
$4.58
+0.28 (+6.51%)
|
Enobosarm
Postmenopausal women with stress urinary incontinence (SUI)
|
Phase 2 |
Phase 2 initiated January 2016. Data to be presented at International Continence Society Annual Meeting, September 13, 2017.
|
| AGN |
$247.11
+2.72 (+1.11%)
|
ABP 215
Biosimilar candidate to Avastin (bevacizumab)
|
PDUFA |
BsUFA (PDUFA) date September 14, 2017. Advisory Committee meeting July 13, 2017.
|
| AMGN |
$173.82
+2.47 (+1.44%)
|
ABP 215
Biosimilar candidate to Avastin (bevacizumab)
|
PDUFA |
BsUFA (PDUFA) date September 14, 2017. Advisory Committee meeting July 13, 2017.
|
| NEOS |
$7.40
+0.1 (+1.37%)
|
NT-0201
Attention deficit hyperactivity disorder (ADHD)
|
PDUFA |
NDA submission announced November 15, 2016. PDUFA estimate November 15, 2017.
|
| GSK |
$44.16
+0.54 (+1.24%)
|
FF/UMEC/VI
Chronic obstructive pulmonary disease (COPD)
|
PDUFA |
Filing announced Novermber 21, 2016. PDUFA estimate September 21, 2017.
|
| INVA |
$12.73
+0.25 (+2%)
|
FF/UMEC/VI
Chronic obstructive pulmonary disease (COPD)
|
PDUFA |
Filing announced November 21, 2016. PDUFA estimate September 21, 2017.
|
| JNJ |
$136.05
+1.13 (+0.85%)
|
Sirukumab
Rheumatoid arthritis
|
PDUFA |
BLA filing announced September 23, 2016. PDUFA estimate September 23, 2017.
|
| MRK |
$66.02
+0.56 (+0.86%)
|
Keytruda
Cancer - Third-line Gastric or Gastroesophageal Junction Adenocarcinoma
|
PDUFA priority review |
PDUFA date under priority review Sept. 22, 2017.
|
| GSK |
$44.16
+0.54 (+1.24%)
|
Sirukumab
Rheumatoid arthritis
|
PDUFA |
BLA filing announced September 23, 2016. PDUFA estimate September 23, 2017.
|
| BMY |
$57.33
+1.26 (+2.25%)
|
CM-040 – Opdivo | PDUFA priority review |
PDUFA date under priority review September 24, 2017.
|
| IPCI |
$2.12
+0.01 (+0.47%)
|
Rexista
Pain relief
|
PDUFA |
PDUFA date September 25, 2017.
|
| AZN |
$35.36
+0.48 (+1.38%)
|
Lynparza - SOLO 2
Second-line ovarian cancer
|
PDUFA priority review |
Data presented March 14, 2017 showed significant PFS benefit. PDUFA date under priority review 3Q 2017. Estimate September 28, 2017 assuming 6-month review.
|
| PTCT |
$17.85
+0.2 (+1.12%)
|
Translarna
Duchenne muscular dystrophy caused by nonsense mutations (nmDMD)
|
PDUFA |
Received a Refusal to File letter for their NDA Filing - February 23 2016. Appeal rejected October 17, 2016. Decision made to resubmit NDA during 1Q 2017 under protest. New PDUFA date October 24, 2017. Advisory Committee Meeting September 28, 2017.
|
| NVO |
$43.67
-0.04 (-0.09%)
|
Fast-acting insulin aspart
Type 1 and type 2 diabetes
|
PDUFA |
NDA filing resubmission noted March 29, 2017 in response to CRL issued October 2016. Estimated latest possible PDUFA date - September 29, 2017 using 6-month timeline. Waiting for official date from company.
|
| ABUS |
$3.75
+0.05 (+1.35%)
|
ARB-1467
Hepatitis B (HBV)
|
Phase 2 |
Phase 2 Cohort 4 data due 3Q 2017.
|
| ALDX |
$4.25
+0.05 (+1.19%)
|
ADX-102
Dry eye syndrome
|
Phase 2a |
Phase 2a enrollment commenced June 6, 2017 with data due 3Q 2017.
|
| AMRN |
$3.31
+0.1 (+3.12%)
|
Vascepa REDUCE-IT outcomes trial
High Triglycerides With Mixed Dyslipidemia
|
– |
Interim analysis announced September 12, 2016 - trial to proceed.Second interim analysis due late 3Q 2017. Final data due mid-2018.
|
| ANTH |
$1.82
+0.02 (+1.11%)
|
Blisibimod
IgA nephropathy
|
Phase 2 |
Phase 2 primary endpoint not met following interim analysis. Trial to continue. Data due 3Q 2017.
|
| APRI |
$1.09
+0.08 (+7.92%)
|
Vitaros
Erectile dysfunction
|
NDA Filing |
NDA resubmission planned for 3Q 2017.
|
| ARDX |
$5.00
+0.25 (+5.26%)
|
RDX7675
Hyperkalemia
|
Phase 2 |
Onset of action trial data due 3Q 2017.
|
| AST |
$3.55
+0.15 (+4.41%)
|
AST-OPC1 SCiSTAR
Cervical spinal cord injury
|
Phase 1/2 |
Phase 1/2 six and nine-month data released January 24, 2017. 12-month efficacy and safety data for this cohort, as well as 6-month efficacy and safety data for the currently-enrolling AIS-A 20 million cell and AIS-B 10 million cell cohorts, due 3Q 2017. Data Monitoring Committee (DMC) noted April 25 to continue trial as planned.
|
| AXON |
$24.00
+0.2 (+0.84%)
|
Intepirdine - MINDSET
Alzheimer's disease
|
Phase 3 |
Phase 3 data are due September 2017.
|
| AXSM |
$5.40
+0.15 (+2.86%)
|
AXS-02 COAST-1
Knee Osteoarthritis Associated with Bone Marrow Lesions
|
Phase 3 |
Phase 3 commenced March 2016. Interim analysis due 3Q 2017.
|
| AZRX |
$3.58
-0.03 (-0.83%)
|
MS1819-SD
Exocrine pancreatic insufficiency (EPI) caused by chronic pancreatitis (CP)
|
Phase 2 |
Announced December 21, 2016 that Phase 2 enrollment has commenced. Trial completion due 3Q 2017.
|
| BMY |
$57.33
+1.26 (+2.25%)
|
CM-511 – Opdivo + Yervoy
First-line Melanoma
|
Phase 3 |
Phase 3 data due 2Q or 3Q 2017.
|
| BTX |
$3.15
+0.17 (+5.7%)
|
AST-OPC1 - SCiStar
Cervical spinal cord injury
|
Phase 1/2 |
Phase 1/2 six and nine-month data released January 24, 2017. 12-month efficacy and safety data for this cohort, as well as 6-month efficacy and safety data for the currently-enrolling AIS-A 20 million cell and AIS-B 10 million cell cohorts, due 3Q 2017. Data Monitoring Committee (DMC) noted April 25 to continue trial as planned.
|
| CBAY |
$5.13
+0.02 (+0.39%)
|
MBX-8025
Primary biliary cholangitis (PBC)
|
Phase 2 |
Phase 2 top-line data released late May 2016. Second trial initiation announced December 7, 2016 with data due 3Q 2017.
|
| CRIS |
$2.11
+0.07 (+3.43%)
|
CUDC-907
Diffuse-large B-cell lymphoma (DLBCL)
|
Phase 2 |
Phase 2 initial data due 3Q 2017.
|
| CUR |
$5.63
+0.26 (+4.84%)
|
NSI-189
Major depressive disorder
|
Phase 2 |
Phase 2 completion of dosing announced May 17, 2017. Data are due 3Q 2017.
|
| FCSC |
$3.31
+0 (+0%)
|
FCX-007
Recessive dystrophic epidermolysis bullosa
|
Phase 1/2 |
Phase 1/2 initiation of dosing announced February 23, 2017. Phase 1 data due 3Q 2017.
|
| FGEN |
$32.35
+0.75 (+2.37%)
|
Pamrevlumab (FG-3019)
Idiopathic pulmonary fibrosis
|
Phase 2 |
Data due 3Q 2017.
|
| FOLD |
$10.09
+0.15 (+1.51%)
|
SD-101
Epidermolysis Bullosa (EB)
|
Phase 3 |
Phase 3 enrollment completed April 3, 2017 with top-line data due 3Q 2017.
|
| GEMP |
$11.30
-0.02 (-0.18%)
|
Gemcabene - ROYAL-1
Heterozygous Familial Hypercholesterolemia (HeFH)
|
Phase 2b |
Phase 2b data due 3Q 2017.
|
| GILD |
$70.48
+2.98 (+4.41%)
|
GS-0976
Nonalcoholic steatohepatitis (NASH)
|
Phase 2 |
Phase 2 data due 3Q 2017.
|
| GLPG |
$78.56
+1.21 (+1.56%)
|
GLPG1690 - FLORA
Idiopathic pulmonary fibrosis
|
Phase 2a |
Phase 2a top-line data due 3Q 2017.
|
| GTXI |
$4.58
+0.28 (+6.51%)
|
Enobosarm
Breast cancer - metastatic or locally advanced, ER+/AR+ breast cancer
|
Phase 2 |
Phase 2 initial data released December, 8 2016. Top-line data due 3Q 2017.
|
| INSM |
$17.59
+0.8 (+4.76%)
|
ARIKAYCE
Non-tuberculous Mycobacterial Lung Disease
|
Phase 3 |
Phase 3 data due September 2017 timeframe plus or minus a month.
|
| KDMN |
$3.49
-0.08 (-1.97%)
|
KD025
Chronic graft-versus-host disease (cGVHD)
|
Phase 2 |
Phase 2 initiated September 2016. Data due 3Q 2017.
|
| MYOK |
$13.95
+0.25 (+1.82%)
|
MYK-461 - PIONEER-HCM
Hypertrophic cardiomyopathy (HCM)
|
Phase 2 |
Phase 2 dosing initiated November 2016. Top-line data due 3Q 2017.
|
| NBRV |
$10.50
+1.19 (+12.78%)
|
Lefamulin - LEAP 1
Moderate to severe Community Acquired Bacterial Pneumonia (CABP)
|
Phase 3 |
Phase 3 enrollment completion noted April 11, 2017 with data due 3Q 2017.
|
| NKTR |
$19.50
+0.34 (+1.77%)
|
Inhaled Amikacin Solution (BAY41-6551T)
Gram-Negative Pneumonia (INHALE 1)
|
Phase 3 |
Phase 3 data due 3Q 2017.
|
| NVO |
$43.67
-0.04 (-0.09%)
|
Semaglutide (NN9536)
Obesity
|
Phase 2 |
Phase 2 data due 3Q 2017.
|
| OTIC |
$17.75
+0.25 (+1.43%)
|
OTO-104 AVERTS-1
Ménière's disease
|
Phase 3 |
Second Phase 3 trial initiated March 2016. Data due 3Q 2017.
|
| PRQR |
$4.98
+0.07 (+1.53%)
|
QR-010
Cystic Fibrosis
|
Phase 1b |
Phase 1b top-line data due September 2017.
|
| PRTA |
$56.99
+0.38 (+0.67%)
|
PRX003
Psoriatic Arthritis
|
Phase 1b |
Phase 1b data due 3Q 2017.
|
| RDHL |
$8.96
-0.18 (-1.97%)
|
BEKINDA
IBS-D
|
Phase 2 |
Phase 2 top-line data due 3Q 2017.
|
| SAGE |
$84.94
+1.63 (+1.96%)
|
SAGE-547
SRSE
|
Phase 3 |
Phase 3 data due 3Q 2017 - updated timeline received May 9, 2017.
|
| TTPH |
$7.88
-0.08 (-1.01%)
|
Eravacycline (TP-434) - IGNITE4
cIAI (complicated intra-abdominal infections)
|
Phase 3 |
Phase 3 data due 3Q 2017.
|
| VBLT |
$4.85
-0.1 (-2.02%)
|
VB-111
Recurrent glioblastoma (rGBM) cancer
|
Phase 3 |
Phase 3 completion of enrollment announced January 6, 2017. Interim analysis due 3Q 2017. Full data due early 2018.
|
| VSAR |
$17.20
+0.25 (+1.47%)
|
VRS-317 VELOCITY
Growth hormone deficiency, or GHD - pediatric
|
Phase 3 |
Phase 3 top-line data due September 2017.
|
| VYGR |
$10.27
+0.15 (+1.48%)
|
VY-AADC01
Advanced Parkinson’s disease
|
Phase 1b |
Phase 1b trial onoging. Interim data released December 7, 2016. Cohort 3 data due 3Q 2017. Placebo-controlled trial to commence 4Q 2017.
|
| ZGNX |
$15.00
+0 (+0%)
|
ZX008 - (Study 1)
Dravet syndrom
|
Phase 3 |
Phase 3 data due 3Q 2017.
|
| ZYNE |
$7.30
+0 (+0%)
|
ZYN002
Fragile X syndrome
|
Phase 2 |
Phase 2 trial initiation announced January 3, 2017. Data are due 3Q 2017.
|
| FLXN |
$20.16
+0.64 (+3.28%)
|
Zilretta - FX006
Osteoarthritis of the knee
|
PDUFA |
PDUFA date October 6, 2017.
|
| MYL |
$39.01
+0.74 (+1.93%)
|
MYL-1401H
Neulasta biosimilar
|
PDUFA |
PDUFA date October 9, 2017.
|
| ACRX |
$2.40
-0.1 (-4%)
|
ARX-04 (SAP303)
Moderate-to-severe acute pain following a surgical procedure
|
PDUFA |
PDUFA date October 12, 2017. Noted June 7, 2017 that an Advisory Committee Meeting is no longer planned.
|
| JNJ |
$136.05
+1.13 (+0.85%)
|
STELARA (USTEKINUMAB)
Plaque psoriasis
|
PDUFA |
sBLA filing announced December 15, 2016. PDUFA estimate October 15, 2017.
|
| AMAG |
$18.20
+0.45 (+2.54%)
|
Makena - auto injector
Reduce the risk of preterm birth in women with a singleton pregnancy
|
sNDA Filing |
sNDA filing announced April 17, 2017. PDUFA date estimated October 17, 2017 assuming 6-month priority review.
|
| ATRS |
$3.01
+0.06 (+2.02%)
|
Makena - auto injector
Preterm birth
|
– |
sNDA filing announced April 17, 2017. PDUFA date October 17, 2017 assuming 6-month priority review.
|
| ATRS |
$3.01
+0.06 (+2.02%)
|
VIBEX QuickShot
Testosterone deficiency
|
PDUFA |
PDUFA date October 20, 2017.
|
| EIGR |
$7.10
+0.15 (+2.16%)
|
Pegylated Interferon Lambda (LIMT HDV)
Hepatitis delta virus (HDV)
|
Phase 2 |
Phase 2 dosing commenced October 2016. Interim data due at AASLD, October 20 -24, 2017.
|
| JNJ |
$136.05
+1.13 (+0.85%)
|
SIMPONI ARIA
Psoriatic arthritis (PsA)
|
PDUFA |
sBLA filing announced December 21, 2016. PDUFA date estimate October 21, 2017.
|
| JNJ |
$136.05
+1.13 (+0.85%)
|
SIMPONI ARIA
Ankylosing Spondylitis
|
PDUFA |
sBLA filing announced December 21, 2016. PDUFA date estimate October 21, 2017.
|
| ALXN |
$126.23
+2.65 (+2.14%)
|
Eculizumab
Refractory generalized myasthenia gravis (gMG)
|
PDUFA |
(sBLA) PDUFA date October 23, 2017.
|
| GSK |
$44.16
+0.54 (+1.24%)
|
Shingrix
Shingles
|
PDUFA |
BLA filing announced October 24, 2016. PDUFA estimate October 24, 2017.
|
| TSRO |
$149.77
+7.64 (+5.38%)
|
Rolapitant - intravenous (IV)
Prevention of chemotherapy induced nausea and vomiting, or CINV in HEC patients
|
PDUFA |
CRL January 11 2017. Resubmission noted with new PDUFA October 25, 2017.
|
| EGRX |
$81.02
+0.24 (+0.3%)
|
Ready-to-dilute (RTD) Pemetrexed Injection
Nonsquamous Non-Small Cell Lung Cancer (NSCLC) and Mesothelioma
|
PDUFA |
PDUFA date October 30, 2017.
|
| EARS |
$0.65
+0.01 (+1.55%)
|
AM-111 HEALOS
Acute inner ear hearing loss
|
Phase 3 |
Phase 3 HEALOS data due fall of 2017.
|
| SYRS |
$16.86
-0.32 (-1.86%)
|
SY-1425
Relapsed or refractory Acute myeloid leukemia (AML) and relapsed high-risk Myelodysplastic Syndrome (MDS) - cancer
|
Phase 2 |
Phase 2 initiated September 2016. Preliminary data due fall of 2017.
|
| KERX |
$6.39
+0.06 (+0.95%)
|
Auryxia
Iron deficiency anemia in non-dialysis dependent CKD patients
|
PDUFA |
(sNDA) PDUFA date November 6, 2017.
|
| HRTX |
$15.40
+0.4 (+2.67%)
|
CINVANTI (HTX-019)
Prevention of chemotherapy-induced nausea and vomiting (CINV)
|
PDUFA |
PDUFA date November 12, 2017.
|
| ARDX |
$5.00
+0.25 (+5.26%)
|
Tenapanor (T3MPO-2)
Constipation-predominant irritable bowel syndrome (IBS-C)
|
Phase 3 |
Phase 3 data due early 4Q 2017. Estimate November 15, 2017 as latest possible date using company guidance of "early 4Q".
|
| RARE |
$65.66
-0.74 (-1.12%)
|
rhGUS
Mucopolysaccharidosis 7 (MPS 7)
|
PDUFA priority review |
Phase 3 data released July 2016. Primary endpoint hit. Secondary missed. PDUFA date under priority review November 16, 2017.
|
| JNJ |
$136.05
+1.13 (+0.85%)
|
Guselkumab
Plaque psoriasis
|
PDUFA |
BLA submission announced November 17, 2016. PDUFA date estimate November 17, 2017.
|
| KITE |
$93.99
+0.45 (+0.48%)
|
Axicabtagene ciloleucel (KTE-C19) - ZUMA-1
Refractory Non-Hodgkin's Lymphoma (NHL) - cancer
|
PDUFA priority review |
PDUFA date under priority review November 29, 2017.
|
| CLDX |
$2.58
+0.04 (+1.57%)
|
Glembatumumab vedotin, varlilumab, Opdivo or Keytruda
Cancer - melanoma
|
Phase 2 |
Phase 2 continues to enroll. Glembatumumab vedotin and varlilumab arm data due fall of 2017.
|
| JNJ |
$136.05
+1.13 (+0.85%)
|
Rilpivirine and Dolutegravir
HIV
|
PDUFA priority review |
Primary endpoint of non inferiority met - December 19, 2016. NDA filing announced June 5, 2017. Priority review requested - estimate PDUFA December 5, 2017 (6 month timeline) assuming priority review granted.
|
| NVO |
$43.67
-0.04 (-0.09%)
|
Semaglutide
Type 2 diabetes
|
PDUFA |
NDA filed December 5, 2016. PDUFA estimate December 5, 2017.
|
| BLUE |
$118.50
-1.8 (-1.5%)
|
LentiGlobin - HGB-206
Sickle disease
|
Phase 1/2 |
Update at ASH 2016. Further data due at ASH 2017. Exact date TBC.
|
| ACRS |
$26.02
-0.21 (-0.8%)
|
A-101
Seborrheic keratosis (SK)
|
PDUFA |
PDUFA date is December 24, 2017
|
| VRX |
$15.50
+1.82 (+13.3%)
|
Luminesse
Eye Brightener
|
PDUFA |
PDUFA date December 27, 2017.
|
| ABBV |
$73.18
+1.84 (+2.58%)
|
Imbruvica - PHOENIX
First-line Diffuse large B-cell lymphoma (DLBCL)
|
Phase 3 |
Phase 3 interim data possibly due 2H 2017.
|
| ABBV |
$73.18
+1.84 (+2.58%)
|
Venclexta (MURANO)
Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)
|
Phase 3 |
Phase 3 data due 2017 as per 1Q earnings call.
|
| ABBV |
$73.18
+1.84 (+2.58%)
|
Risankizumab
Psoriasis
|
Phase 3 |
Phase 3 data due by the end of 2017.
|
| ABBV |
$73.18
+1.84 (+2.58%)
|
Elagolix
Uterine Fibroids
|
Phase 3 |
Phase 3 initiated in January 2016. Data due late 2017.
|
| ABBV |
$73.18
+1.84 (+2.58%)
|
Risankizumab
Psoriatic Arthritis
|
Phase 2b |
Phase 2b data due 2017.
|
| ABBV |
$73.18
+1.84 (+2.58%)
|
Rova-T (TRINITY)
Third-line Small Cell Lung Cancer
|
Phase 2 |
Phase 2 pivotal data due 2017.
|
| ABBV |
$73.18
+1.84 (+2.58%)
|
ABT-494
Atopic Dermatitis
|
Phase 2b |
Phase 2b data due 2017.
|
| ACHN |
$4.30
+0.07 (+1.65%)
|
JNJ-4178 - OMEGA-1
Hepatitis C (HCV)
|
Phase 2b |
Phase 2b trial initiation announced November 30, 2016. Data due 2H 2017.
|
| ADRO |
$11.15
+0.3 (+2.76%)
|
CRS-207 with anti-PD1
Mesothelioma - cancer
|
Phase 2 |
Phase 2 trial to be initiated 2Q 2017 with early data due 2H 2017.
|
| ADXS |
$6.34
+0.25 (+4.11%)
|
Axalimogene filolisbac + durvalumab
Recurrent or refractory HPV-associated cervical cancer and head & neck cancer
|
Phase 1/2 |
Phase 1/2 updated data due 2H 2017.
|
| ADXS |
$6.34
+0.25 (+4.11%)
|
Axalimogene filolisbac
Anal cancer (FAWCETT)
|
Phase 2 |
Phase 2 initiated June 2016. Preliminary update due 2H 2017.
|
| AFMD |
$2.08
+0.02 (+1.22%)
|
AFM13 with Keytruda
Hodgkin Lymphoma - Cancer
|
Phase 1b |
Phase 1b update 2H 2017.
|
| AFMD |
$2.08
+0.02 (+1.22%)
|
AFM13
Hodgkin Lymphoma - Cancer
|
Phase 2 |
Phase 2a update due 2H 2017 with full data due 2019.
|
| AGIO |
$57.42
+0.64 (+1.12%)
|
AG-120
IDH1m Relapsed/Refractory AML - cancer
|
NDA Filing |
NDA filing due by end of 2017.
|
| AGN |
$247.11
+2.72 (+1.11%)
|
Cortisol Analog
Dry Eye disease
|
Phase 3 |
Phase 3 trial to be initiated 2H 2017.
|
| AIMT |
$19.90
+0.74 (+3.86%)
|
AR101
Peanut Allergy
|
Phase 3 |
Phase 3 initiated January 2016. Enrollment completion announced November 28, 2016. Top-line data due 4Q 2017.
|
| AKAO |
$22.49
-0.91 (-3.89%)
|
Plazomicin - CARE
Serious bacterial infections due to carbapenem-resistant Enterobacteriaceae (CRE)
|
NDA Filing |
Phase 3 data released December 12, 2016 - primary endpoint met. NDA filing due 2H 2017.
|
| ANAB |
$24.05
+0.65 (+2.78%)
|
ANB020
Moderate-to-severe adult atopic dermatitis
|
Phase 2 |
Phase 2a trial initiated 1Q 2017 with data due 2H 2017.
|
| ANAB |
$24.05
+0.65 (+2.78%)
|
ANB020
Severe adult peanut allergy
|
Phase 2a |
Phase 2a trial initiated 1Q 2017 with data due 2H 2017.
|
| ARGS |
$0.42
-0.04 (-7.29%)
|
AGS-003
Early stage renal cell carcinoma (RCC) - cancer
|
Phase 2 |
Phase 2 trial initial data due 2H 2017.
|
| ARGX |
$20.01
-0.58 (-2.82%)
|
ARGX-110
Relapsed/refractory cutaneous T-cell lymphoma (CTCL)
|
Phase 2 |
Phase 2 interim data due by the end of 2017 with top-line data due by the end of 2018.
|
| ARGX |
$20.01
-0.58 (-2.82%)
|
ARGX-110
Acute myeloid leukemia (AML)
|
Phase 1/2 |
Phase 1/2 interim data due by the end of 2017.
|
| ARNA |
$16.19
-0.41 (-2.48%)
|
Etrasimod
Ulcerative colitis
|
Phase 2 |
Phase 2 data due by the end of 2017.
|
| ARRY |
$8.76
-0.23 (-2.56%)
|
Encorafenib and cetuximab - BEACON CRC
BRAF-Mutant Colorectal Cancer
|
Phase 3 |
Phase 3 initiated June 2016. SPA announced September 2016. Randomization part of trial now enrolling. Expects to present early data from the safety lead-in later in 2017..
|
| ATNM |
$1.23
+0.02 (+1.65%)
|
Actimab-A
Acute Myeloid Leukemia (AML)
|
Phase 2 |
Phase 2 to initiated September 2016. Interim analysis due 2H 2017.
|
| AXON |
$24.00
+0.2 (+0.84%)
|
Nelotanserin
DLB patients experiencing REM Behavior Disorder (RBD)
|
Phase 2 |
Phase 2 data due 2H 2017.
|
| AXON |
$24.00
+0.2 (+0.84%)
|
Intepirdine - HEADWAY-DLB
Dementia with Lewy bodies (DLB)
|
Phase 2b |
Phase 2b data due 4Q 2017
|
| AXSM |
$5.40
+0.15 (+2.86%)
|
AXS-02 CREATE-1
Complex regional pain syndrome (CRPS)
|
Phase 3 |
Initiated July 2015. Expect to complete trial by end of 2017 with interim efficacy analysis due 4Q 2017.
|
| AZN |
$35.36
+0.48 (+1.38%)
|
Tralokinumab (STRATOS2)
Severe, uncontrolled asthma
|
Phase 3 |
Phase 3 data due 2H 2017.
|
| AZN |
$35.36
+0.48 (+1.38%)
|
Tagrisso
First-line lung cancer
|
Phase 3 |
Phase 3 data due 2H 2017.
|
| AZN |
$35.36
+0.48 (+1.38%)
|
Moxetumomab
Cancer - leukaemia
|
Phase 3 |
Phase 3 data due 2H 2017.
|
| AZN |
$35.36
+0.48 (+1.38%)
|
Lynparza
First-line ovarian cancer
|
Phase 3 |
Phase 3 data due 2H 2017.
|
| AZN |
$35.36
+0.48 (+1.38%)
|
Durvalumab +/- tremelimumab (KESTREL)
Head & neck cancer
|
Phase 3 |
Phase 3 data due 2H 2017.
|
| AZN |
$35.36
+0.48 (+1.38%)
|
Durvalumab +/- tremelimumab (ARCTIC)
Lung cancer
|
Phase 3 |
Phase 3 data 4Q 2017.
|
| BIIB |
$280.57
+1.97 (+0.71%)
|
BAN2401 (Aβ mAb)
Alzheimer’s disease
|
Phase 2 |
Phase 2 data due by the end of 2017.
|
| BIIB |
$280.57
+1.97 (+0.71%)
|
BG00011 (STX-100)
Idiopathic pulmonary fibrosis (IPF)
|
Phase 2 |
Phase 2 to be completed 2017.
|
| BLPH |
$1.37
-0.02 (-1.44%)
|
INOpulse delivery device
Pulmonary Arterial Hypertension (PAH)
|
Phase 3 |
Phase 3 commenced enrollment June 2016. Interim analysis due 4Q 2017 with top-line data due mid-2018.
|
| BLRX |
$0.87
+0 (+0.11%)
|
BL-8040 in combination with KEYTRUDA - COMBAT trial
Pancreatic cancer
|
Phase 2 |
Phase 2 initiated September 2016. Partial data due 2H 2017. Full data due 2H 2018.
|
| BLRX |
$0.87
+0 (+0.11%)
|
BL-8040
Mobilization and collection of bone marrow stem cells
|
Phase 2 |
Phase 2 trial initiated March 2016. Partial data released March 20, 2017 with topline results by the end of 2017 with Phase 2/3 trial to be initiated 2H 2017.
|
| BLUE |
$118.50
-1.8 (-1.5%)
|
Lenti-D - Starbeam
Childhood cerebral adrenoleukodystrophy (CCALD)
|
Phase 2/3 |
Phase 2/3 trial initiated October 2013. Interim data released at AAN Conference April 20, 2016. Full data due by the end of 2017.
|
| BMY |
$57.33
+1.26 (+2.25%)
|
CM-459 – Opdivo
First-line Hepatocellular carcinoma (HCC) - cancer
|
Phase 3 |
Phase 3 data due 2H 2017.
|
| BMY |
$57.33
+1.26 (+2.25%)
|
CM-214 – Opdivo + Yervoy
First-line Renal cell carcinoma (RCC)
|
Phase 3 |
Phase 3 data due 2H 2017.
|
| BOLD |
$18.44
+0.67 (+3.77%)
|
AT982
Pompe disease
|
Phase 1/2 |
Preliminary proof of concept data due 2H 2017.
|
| BOLD |
$18.44
+0.67 (+3.77%)
|
AT342 - VALENS
Crigler-Najjar
|
Phase 1/2 |
Phase 1/2 preliminary data due 4Q 2017.
|
| BOLD |
$18.44
+0.67 (+3.77%)
|
AT132 - XLMTM
X-Linked Myotubular Myopathy
|
Phase 1/2 |
Phase 1/2 preliminary data due 4Q 2017.
|
| BPTH |
$0.45
+0.02 (+4.65%)
|
BP-1001
Acute myeloid leukemia (AML)
|
Phase 2 |
Phase 2 first patient enrolled November 2016. Interim analysis due by the end of 2017.
|
| BYSI |
$32.50
+2.49 (+8.27%)
|
Plinabulin (Trial 106)
Prevention of neutropenia
|
Phase 2/3 |
First data due 2H 2017.
|
| BYSI |
$32.50
+2.49 (+8.27%)
|
Plinabulin (Trial 105)
Prevention of neutropenia
|
Phase 2/3 |
Phase 2/3 enrollment announced April 25, 2017. Data from Phase 2 portion due 2H 2017. Interim data from Phase 3 portion due 1H 2018.
|
| CALA |
$15.00
-0.35 (-2.28%)
|
CB-839 + nivolumab
Renal cell carcinoma, malignant melanoma and non-small cell lung cancer
|
Phase 1/2 |
Phase 1/2 enrolment commenced August 2016. Initial data due 2H 2017.
|
| CAPR |
$0.68
-0.02 (-2.87%)
|
CAP-1002 HOPE-Duchenne
Duchenne Muscular Dystrophy (DMD)
|
Phase 1/2 |
Phase 1/2 data released April 25, 2017. Noted improvement in certain measures of cardiac and upper limb function. 12-month data due 4Q 2017.
|
| CARA |
$19.88
+0.38 (+1.95%)
|
IV CR845
Acute pain
|
Phase 3 |
Phase 3 initiated September 2015. Placed on clinical hold February 2016. Clinical hold released April 2016 with enrollment resuming June 2016. Interim conditional power analysis conducted June 21, 2017 - trial completion due 4Q 2017.
|
| CBIO |
$4.51
+0.13 (+2.97%)
|
CB 2679d/ ISU304
Hemophilia B
|
Phase 1/2 |
Phase 1/2 completion of dosing announced June 14, 2017 with data due by the end of 2017.
|
| CDTX |
$6.90
-0.35 (-4.83%)
|
CD101 IV - STRIVE
Candidemia
|
Phase 2 |
Phase 2 initiated June 2016. Data due 4Q 2017.
|
| CELG |
$133.68
+0.85 (+0.64%)
|
REVLIMID - RELEVANCE
Newly Diagnosed Follicular Lymphoma
|
Phase 3 |
Phase 3 data due 2017.
|
| CELG |
$133.68
+0.85 (+0.64%)
|
REVLIMID - AUGMENT NHL-007
Relapsed or Refractory Follicular Lymphoma
|
Phase 3 |
Phase 3 data due 2017.
|
| CELG |
$133.68
+0.85 (+0.64%)
|
Ozanimod - SUNBEAM
Relapsing Multiple Sclerosis
|
Phase 3 |
Phase 3 data released February 17, 2017 - primary endpoint met. Full data due 2H 2017.
|
| CELG |
$133.68
+0.85 (+0.64%)
|
OTEZLA - BCT-002 RELIEF
Behçet’s Disease
|
Phase 3 |
Phase 3 data due 2017.
|
| CELG |
$133.68
+0.85 (+0.64%)
|
ABRAXANE - PANC-003 apact
Adjuvant Therapy in Surgically Resected Pancreatic Cancer
|
Phase 3 |
Phase 3 data due 2017.
|
| CELG |
$133.68
+0.85 (+0.64%)
|
ABRAXANE - NSCL-003 abound.sqm
First-line late stage Squamous Non-small cell lung cancer (NSCLC)
|
Phase 3 |
Phase data due 2017.
|
| CELG |
$133.68
+0.85 (+0.64%)
|
ABRAXANE - NSCL-003 abound.70+
Elderly Non-small cell lung cancer (NSCLC)
|
Phase 3 |
Phase 3 data due 2017.
|
| CELG |
$133.68
+0.85 (+0.64%)
|
OTEZLA
Ulcerative Colitis
|
Phase 2 |
Phase 2 data due 2017. Phase 3 trial to be initiated 2018.
|
| CELG |
$133.68
+0.85 (+0.64%)
|
GED-0301
Ulcerative Colitis
|
Phase 2 |
Phase 2 data due 2017.
|
| CELG |
$133.68
+0.85 (+0.64%)
|
CC-486 with fulvestrant
ER+, HER2 breast cancer
|
Phase 2 |
Phase 2 data due 2017.
|
| CELG |
$133.68
+0.85 (+0.64%)
|
Durvalumab - FUSION
Relapsed and/or refractory multiple myeloma (RRMM), myelodysplastic syndromes and AML
|
Phase 1/2 |
Phase 1/2 data due 2017.
|
| CEMP |
$4.55
+0.3 (+7.06%)
|
Taksta - Fusidic acid
Refractory infections in bones and joints
|
Phase 2/3 |
Phase 2/3 data due by the end of 2017.
|
| CERU |
$0.38
+0.02 (+6.16%)
|
CRLX301
Solid tumours - cancer
|
Phase 2a |
Phase 2a portion of Phase 1/2a trial commenced dosing June 2016. Initial data due in 2017.
|
| CERU |
$0.38
+0.02 (+6.16%)
|
CRLX101, in combination with LYNPARZA
Solid tumors - cancer
|
Phase 1/2 |
Phase 1/2 trial commenced dosing May 2016. Top-line data due 2017.
|
| CERU |
$0.38
+0.02 (+6.16%)
|
CRLX101 and paclitaxel
Platinum-resistant ovarian cancer
|
Phase 2 |
Further data due in 2017.
|
| CLRB |
$1.59
+0.08 (+5.3%)
|
CLR 131
Various lymphoma
|
Phase 2 |
Phase 2 trial initiation announced March 30, 2017. Initial data due 2H 2017.
|
| CLSD |
$8.81
+0.2 (+2.31%)
|
Suprachoroidal CLS-TA - HULK
Diabetic macular edema (DME)
|
Phase 1/2 |
Phase 1/2 enrollment completion announced April 20, 2017. Preliminary data due 2H 2017.
|
| CNCE |
$14.63
+0.82 (+5.94%)
|
CTP-656
Cystic fibrosis
|
Phase 2 |
Phase 2 trial initiation announced December 21, 2016. Data due by end of 2017.
|
| CORT |
$12.09
+0.02 (+0.17%)
|
CORT125134
Cushing’s syndrome
|
Phase 2 |
Phase 2 trial initiated 2Q 2016. Data due by the end of 2017.
|
| CPRX |
$2.75
+0.04 (+1.48%)
|
Firdapse
Congenital Myasthenic Syndromes (CMS)
|
Phase 3 |
Phase 3 data due 2H 2017.
|
| CPRX |
$2.75
+0.04 (+1.48%)
|
Firdapse
Lambert-Easton Myasthenic Syndrome (LEMS)
|
Phase 3 |
Refusal to file letter reported on February 17, 2016. Announced that enrollment had commenced in second Phase 3 trial on December 15, 2016, with data and NDA resubmission due in 2017.
|
| CRBP |
$5.95
+0 (+0%)
|
Anabasum (Resunab)
Dermatomyositis
|
Phase 2 |
Phase 2 data due 4Q 2017.
|
| CRMD |
$0.43
+0.01 (+3.7%)
|
Neutrolin - LOCK-IT 100
Hemodialysis patients with central venous catheters
|
Phase 3 |
Phase 3 enrollment to be completed 2Q 2018. Data due end of 2018 with interim analysis possibly due 4Q 2017.
|
| CTIC |
$3.37
+0 (+0%)
|
PIXUVRI
B-cell non-Hodgkin lymphoma
|
– |
Top-line data from confirmatory trial required for full EMA approval due by end of 2017.
|
| CYTK |
$14.45
+0.2 (+1.4%)
|
CK-2127107
Spinal muscular atrophy (SMA)
|
Phase 2 |
Phase 2 initiated January 2016. Data are due 2H 2017.
|
| CYTK |
$14.45
+0.2 (+1.4%)
|
Tirasemtiv - VITALITY
Amyotrophic lateral sclerosis (ALS)
|
Phase 3 |
Phase 3 data are due 4Q 2017.
|
| DBVT |
$35.87
+0.93 (+2.66%)
|
Viaskin Peanut (REALISE)
Peanut allergy
|
Phase 3 |
Phase 3 completion of enrollment announced March 10, 2017. Data due 2H 2017.
|
| DBVT |
$35.87
+0.93 (+2.66%)
|
Viaskin Milk
Cow’s milk protein allergy (CMPA)
|
Phase 1/2 |
Phase 1/2 data due 2H 2017.
|
| DBVT |
$35.87
+0.93 (+2.66%)
|
Viaskin Peanut (PEPITES)
Peanut allergy
|
Phase 3 |
Phase 3 completion of enrollment announced March 10, 2017. Data due 2H 2017.
|
| DCTH |
$0.24
-0.03 (-11.27%)
|
Melphalan Hepatic Delivery System (Melphalan HDS)
Hepatocellular carcinoma (HCC) - cancer
|
Phase 3 |
Phase 3 initiated February 2016. Ongoing as of November 2016. Interim safety analysis due 2H 2017.
|
| DMTX |
$1.55
+0.05 (+3.33%)
|
DTX301
Ornithine Transcarbamylase (OTC) Deficiency
|
Phase 1/2 |
Phase 1/2 trial initiated December 2016. Initial data due 2H 2017.
|
| DRRX |
$1.48
+0.03 (+2.06%)
|
POSIMIR - PERSIST 3
Post-operative pain relief
|
Phase 3 |
CRL Feb 12 2014. Phase 3 commenced November 2015 in response to CRL. Enrollment originally expected to take one year but the company announced ammendments to the trial on April 7, 2016, which will result in time added to complete the trial. Noted June 22, 2017 that enrollment has been completed with top-line data due 4Q 2017.
|
| EGLT |
$2.26
-0.08 (-3.42%)
|
Egalet-002
Moderate to severe chronic pain
|
Phase 3 |
Phase 3 to be completed 4Q 2017. NDA planned for 2018.
|
| ESPR |
$42.31
+1.29 (+3.14%)
|
Bempedoic Acid/ Ezetimibe/ Atorvastatin (1002-038)
Hypercholesterolemia
|
Phase 2 |
Phase 2 initiation announced March 7, 2017. Data due 4Q 2017.
|
| EVOK |
$2.56
+0.07 (+2.81%)
|
Gimoti - EVK-001
Female diabetic gastroparesis
|
Phase 3 |
Phase 3 data released July 2016. Primary endpoint not met. However, the company noted December 15, 2016 that following discussions with FDA regarding possible NDA submission, no new efficacy or safety study would be required, if bioequivalence criteria were met in a pharmacokinetic (PK) trial. Confirmed April 4, 2017 that PK data will be released 2H 2017 with NDA filing to be submitted by late 2017 or early 2018.
|
| EXEL |
$24.07
+0.05 (+0.21%)
|
XL184 cabozantinib (CELESTIAL)
Advanced hepatocellular cancer (HCC)
|
Phase 3 |
Phase 3 initiated Sept 2013. Data due 2H 2017.
|
| EYEG |
$1.33
-0.02 (-1.48%)
|
EGP-437
Non-infectious anterior uveitis
|
Phase 3 |
Phase 3 enrollment to be completed 3Q 2017. Top-line data due 4Q 2017
|
| FBIO |
$4.82
+0.03 (+0.63%)
|
Triplex vaccine
Cytomegalovirus (CMV)
|
Phase 2 |
Phase 2 data due 2H 2017.
|
| FLKS |
$4.45
-0.05 (-1.12%)
|
FLX-787
Multiple Sclerosis
|
Phase 2 |
Phase 2 data due by the end of 2017.
|
| GALE |
$0.61
+0.04 (+8%)
|
NeuVax in combination with Herceptin
Breast cancer
|
Phase 2b |
Phase 2b trial ongoing. Interim efficacy analysis due by the end of 2017.
|
| GALT |
$2.38
+0.01 (+0.42%)
|
GR-MD-02
Non-alcoholic steatohepatitis (NASH) with cirrhosis
|
Phase 2b |
Phase 2b top-line data due December 2017.
|
| GILD |
$70.48
+2.98 (+4.41%)
|
GS-9674
Nonalcoholic steatohepatitis (NASH)
|
Phase 2 |
Phase 2 data due 4Q 2017.
|
| GNMX |
$1.32
+1.32 (+-7.69%)
|
AEVI-002 (Anti-LIGHT mAb)
Pediatric onset Crohn's disease
|
Phase 1/2 |
Phase 1/2 data due 2H 2017.
|
| GSK |
$44.16
+0.54 (+1.24%)
|
GSK 165
Rheumatoid arthritis
|
Phase 3 |
Phase 2b data due 2H 2017.
|
| GSK |
$44.16
+0.54 (+1.24%)
|
Nucala
Chronic obstructive pulmonary disease (COPD)
|
Phase 3 |
Phase 3 data due 2017.
|
| GSK |
$44.16
+0.54 (+1.24%)
|
GSK 166
Rheumatoid arthritis
|
Phase 2b |
Phase 2b data due 2H 2017.
|
| GSK |
$44.16
+0.54 (+1.24%)
|
GSK 165
Osteoarthritis
|
Phase 2 |
Phase 2 data due 2H 2017.
|
| GWPH |
$102.91
-1.81 (-1.73%)
|
GWP42006 (CBDV)
Epilepsy
|
Phase 2 |
Phase 2 initiated May 2015. Data due 4Q 2017.
|
| GWPH |
$102.91
-1.81 (-1.73%)
|
Epidiolex
Dravet Syndrome
|
Phase 3 |
Second Phase 3 trial initiated mid April 2015. Data due 2017.
|
| HALO |
$14.83
+0.24 (+1.64%)
|
PEGPH20 in combination with KEYTRUDA
Non-small cell lung cancer (NSCLC)
|
Phase 1b |
Phase 1b enrolment resumed July 2016 under revised protocol. Response rate data possible by end of 2017.
|
| IONS |
$54.72
+0.52 (+0.96%)
|
IONIS-HTT Rx
Huntington's Disease
|
Phase 1/2 |
Phase 1/2 completion of enrollment noted June 22, 2017. Top-line data due around the end of 2017.
|
| IRWD |
$19.61
+0.17 (+0.87%)
|
IW-1973
Type 2 diabetes
|
Phase 2a |
Phase 2a data due 2H 2017.
|
| IRWD |
$19.61
+0.17 (+0.87%)
|
IW-1973
Type 2 diabetes
|
Phase 2 |
Phase 2a data due 2H 2017.
|
| JNCE |
$16.97
+1.23 (+7.81%)
|
JTX-2011
Solid tumors - Cancer
|
Phase 1/2 |
Phase 1/2 trial initiated September 2017.Phase 2 arm initiation announced April 21, 2017. Efficacy data due end of 2017. Phase 1 safety data released at ASCO June 2017.
|
| KDMN |
$3.49
-0.08 (-1.97%)
|
KD025
Idiopathic pulmonary fibrosis (IPF)
|
Phase 2 |
Phase 2 data due 4Q 2017.
|
| KDMN |
$3.49
-0.08 (-1.97%)
|
KD025
Moderate to severe chronic plaque psoriasis
|
Phase 2 |
Phase 2 first patient dosed September 2016. Data due 4Q 2017.
|
| KITE |
$93.99
+0.45 (+0.48%)
|
KTE-C19 (ZUMA-6)
Refractory diffuse large B-cell lymphoma (DLBCL)
|
Phase 1/2 |
Phase 1/2 initiated October 2016. Phase 1 data due 2017.
|
| KURA |
$7.90
+0.8 (+11.27%)
|
Tipifarnib
Lower risk myelodysplastic syndromes (MDS) - cancer
|
Phase 2 |
Phase 2 dosing commenced June 2016. Top-line data due 2H 2017.
|
| LLY |
$84.31
+1.67 (+2.02%)
|
Lasmiditan - SPARTAN
Migraine
|
Phase 3 |
Phase 3 data due 2H 2017. Acquired from CLCD.
|
| LLY |
$84.31
+1.67 (+2.02%)
|
Flortaucipir F 18 (Tau imaging agent)
Alzheimer's disease
|
Phase 3 |
Phase 3 ongoing. Data due 2017 (internal readout).
|
| LLY |
$84.31
+1.67 (+2.02%)
|
Alimta + Keytruda (MK-3475-189/KEYNOTE-189)
First-Line Non-Squamous Non-Small Cell Lung Cancer
|
Phase 3 |
Phase 3 data due late 2017.
|
| LLY |
$84.31
+1.67 (+2.02%)
|
Abemaciclib - JUNIPER
Thrid line KRAS mutation positive Non-small cell lung cancer (NSCLC)
|
Phase 3 |
Phase 3 ongoing. Data due 2017 (internal readout).
|
| LOXO |
$78.58
+1.12 (+1.46%)
|
Larotrectinib (LOXO-101)
Solid tumors that harbor a TRK fusion.
|
Phase 2 |
Announced 76% ORR at ASCO - June 3, 2017. Primary analysis by the end of 2017 with NDA filing late 2017 or early 2018.
|
| MCRB |
$11.56
-0.11 (-0.94%)
|
SER-262
Primary Clostridium Difficile infection (CDI)
|
Phase 1b |
Phase 1b initiated July 2016. Data due 2H 2017
|
| MCRB |
$11.56
-0.11 (-0.94%)
|
SER-287
Mild-to-Moderate Ulcerative Colitis
|
Phase 1b |
Phase 1b initiated December 2015. Completion of enrollment noted June 5, 2017. Data due 2H 2017
|
| MESO |
$7.88
+0.24 (+3.14%)
|
MSC-100-IV
acute graft versus host disease (aGVHD) in children
|
Phase 3 |
Phase 3 data due 2H 2017.
|
| MNOV |
$5.56
+0.09 (+1.65%)
|
MN-166
Progressive multiple sclerosis (progressive MS)
|
Phase 2b |
Phase 2b final data due 2H 2017.
|
| MRK |
$66.02
+0.56 (+0.86%)
|
(MK-3475-189/KEYNOTE-189)
First Line Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
|
Phase 3 |
Phase 3 data due 4Q 2017.
|
| MRK |
$66.02
+0.56 (+0.86%)
|
Ertugliflozin
Type 2 diabetes
|
PDUFA |
PDUFA date set for December 2017 - exact date not provided. December 31 entered as latest possible date for calendar entry purposes only.
|
| MRNS |
$1.36
-0.05 (-3.55%)
|
Ganaxolone
Refractory status epilepticus (RSE)
|
Phase 2 |
Phase 2 trial to commence in 1H 2017 with data due in 2H 2017.
|
| MRNS |
$1.36
-0.05 (-3.55%)
|
Ganaxolone
Postpartum depression
|
Phase 2 |
Phase 2 trial to commence in 1H 2017 with data due in 2H 2017.
|
| MRTX |
$4.05
+0.2 (+5.19%)
|
Sitravatinib plus nivolumab
Non-small cell lung cancer (NSCLC)
|
– |
Phase 2 initial update due 2H 2017.
|
| MRTX |
$4.05
+0.2 (+5.19%)
|
Glesatinib (MGCD265)
Non-small cell lung cancer (NSCLC) patients with driver alterations in MET
|
Phase 2 |
Phase 2 initiated December 2015. Enrollment ongoing - update due 2H 2017.
|
| MRUS |
$16.61
+0.08 (+0.48%)
|
MCLA-128
Solid tumors
|
Phase 1/2 |
Phase 1/2 top-line data due 2H 2017.
|
| MRUS |
$16.61
+0.08 (+0.48%)
|
MCLA-117
Acute myeloid leukemia (AML)
|
Phase 1/2 |
Phase 1/2 interim data due 2H 2017.
|
| MTFB |
$7.55
+0.05 (+0.67%)
|
Iclaprim - REVIVE-2
Acute bacterial skin and skin structure infections (ABSSSI)
|
Phase 3 |
Phase 3 data due 2H 2017.
|
| NBIX |
$47.12
-0.35 (-0.74%)
|
Elagolix
Uterine Fibroids
|
Phase 3 |
Phase 3 initiated by partner Abbvie in January 2016. Data due late 2017.
|
| NLNK |
$7.40
+0.04 (+0.54%)
|
Indoximod + chemotherapy
Acute Myeloid Leukemia (AML)
|
Phase 1/2 |
Phase 1/2 data due 2H 2017.
|
| NLNK |
$7.40
+0.04 (+0.54%)
|
Indoximod + temozolomide
Glioblastoma multiforme cancer
|
Phase 2 |
Phase 2 data due 2H 2017.
|
| NLNK |
$7.40
+0.04 (+0.54%)
|
Indoximod + gemcitabine and nab-paclitaxel
Pancreatic cancer
|
Phase 2 |
Phase 2 data due 2H 2017.
|
| NVS |
$86.34
+3.78 (+4.58%)
|
LEE011: MONALEESA-3
Breast cancer - (post-menopausal)
|
Phase 3 |
Phase 3 data due 2H 2017.
|
| ONCS |
$1.14
-0.02 (-1.72%)
|
ImmunoPulse IL-12
Melanoma - cancer
|
Phase 2 |
Phase 2 enrollment to commence June 2017 with data due 4Q 2017.
|
| ONTX |
$2.09
+0.03 (+1.89%)
|
IV Rigosertib - INSPIRE
2nd-line HR-MDS (high risk myelodysplastic syndromes)
|
Phase 3 |
Original Phase 3 trial did not meet endpoint in Feb 2014. However, following "subgroup analyses" and lack of current treatment options a further Phase 3 trial was initiated in December 2015. Interim analysis due 2H 2017. Enrollment to be completed 1Q 2018.
|
| OTIC |
$17.75
+0.25 (+1.43%)
|
OTO-104 AVERTS-2
Ménière's disease
|
Phase 3 |
Second Phase 3 trial initiated March 2016. Data due by the end of 2017.
|
| PFE |
$34.06
+0.18 (+0.53%)
|
XTANDI (PROSPER)
Non-metastatic high risk hormone-sensitive prostate cancer
|
Phase 3 |
Phase 3 primary completion date June 2017 following change of protocol noted June 9, 2017 with data due later in 2017.
|
| PFE |
$34.06
+0.18 (+0.53%)
|
Xeljanz
Psoriatic arthritis
|
Phase 3 |
PDUFA date December 31, 2017. No exact date given. December 31, 2017 noted as last possible date using guidance of "December 31".
|
| PFE |
$34.06
+0.18 (+0.53%)
|
Ertugliflozin
Type 2 diabetes
|
Phase 3 |
PDUFA date set for December 2017 - exact date not provided. December 31 entered as latest possible date for calendar entry purposes only.
|
| PLX |
$0.82
+0.01 (+1.49%)
|
OPRX-106
Ulcerative Colitis
|
Phase 2 |
Phase 2 trial initiation announced November 30, 2016. Data due around the end of 2017.
|
| PSTI |
$1.39
+0.01 (+0.72%)
|
PLX-PAD (stem cells)
Intermittent claudication, or IC
|
Phase 2 |
Phase 2 put on clinical hold Jun 2013. Lifted Sept 2013. Enrollment completed May 2016. Data are due late 2017.
|
| PTGX |
$12.08
-0.03 (-0.25%)
|
PTG-100
Ulcerative colitis
|
Phase 2b |
Phase 2b initiation announced January 17, 2017. Interim futility analysis 2H 2017.
|
| PULM |
$2.49
+0.11 (+4.62%)
|
PUR0200
COPD
|
Phase 2 |
Phase 2 data due 4Q 2017.
|
| RARE |
$65.66
-0.74 (-1.12%)
|
Aceneuramic acid extended release (Ace-ER)
GNE Myopathy
|
Phase 3 |
Phase 3 data due 2H 2017.
|
| REGN |
$526.53
+4.51 (+0.86%)
|
REGN2222
Respiratory syncytial virus (RSV)
|
Phase 3 |
Phase 3 data due 2H 2017.
|
| REGN |
$526.53
+4.51 (+0.86%)
|
Dupixent (dupilumab) - LIBERTY ASTHMA QUEST
Asthma
|
Phase 3 |
Phase 3 data due 4Q 2017.
|
| REGN |
$526.53
+4.51 (+0.86%)
|
EYLEA + nesvacumab
Diabetic macular edema (DME)
|
Phase 2 |
Phase 2 enrollment completed 4Q 2016. Data due 2H 2017.
|
| REGN |
$526.53
+4.51 (+0.86%)
|
EYLEA + nesvacumab
AMD - age-related macular degeneration
|
Phase 2 |
Phase 2 data due 2H 2017.
|
| RETA |
$29.26
+0.52 (+1.81%)
|
Bardoxolone methyl - CARDINAL
Chronic Kidney Disease Caused by Alport Syndrome
|
Phase 2/3 |
Phase 2/3 trial initiation announced February 23, 2017. Data from Phase 2 part of trial due by the end of 2017.
|
| RETA |
$29.26
+0.52 (+1.81%)
|
Bardoxolone methyl - LARIAT
Pulmonary hypertension due to interstitial lung disease - PH-ILD
|
Phase 2 |
Phase 2 enrollment commenced January 2017. Data due 2H 2017.
|
| RETA |
$29.26
+0.52 (+1.81%)
|
Omaveloxolone - MOTOR
Mitochondrial myopathies (MM)
|
Phase 2 |
Phase 2 initial data due 2H 2017.
|
| RETA |
$29.26
+0.52 (+1.81%)
|
Omaveloxolone - REVEAL
Metastatic melanoma
|
Phase 1/2 |
Phase 1b portion of trial due 2H 2017.
|
| RGLS |
$0.99
+0.04 (+4.3%)
|
RG-012
Renal biopsy study in Alport patients
|
Phase 1/2 |
Phase 1/2 data due year end 2017.
|
| RGNX |
$21.10
+0.6 (+2.93%)
|
RGX-501
Homozygous familial hypercholesterolemia (HoFH)
|
Phase 1/2 |
Phase 1/2 dosing initiated - March 8, 2017. Interim data due by the end of 2017.
|
| RIGL |
$2.78
+0.07 (+2.58%)
|
Fostamatinib
Autoimmune hemolytic anemia (AIHA)
|
Phase 2 |
Phase 2 data from first of two stages due in 2017.
|
| RNN |
$3.01
+0.03 (+0.97%)
|
Supinoxin
Triple negative breast cancer
|
Phase 2a |
Phase 2a initial data due towards the end of 2017.
|
| RNN |
$3.01
+0.03 (+0.97%)
|
RX-3117
Relapsed and refractory pancreatic cancer
|
Phase 2 |
Updated Phase 2a data presented at ASCO GI January 20, 2017. Final data due 2H 2017.
|
| RNN |
$3.01
+0.03 (+0.97%)
|
Archexin
Renal cell carcinoma (RCC) - cancer
|
Phase 2a |
Phase 2a second stage enrolment commenced February 2016. Noted May 4, 2017 an update due later this year.
|
| RTRX |
$19.71
-0.23 (-1.15%)
|
Liquid ursodeoxycholic acid (L-UDCA)
Primary biliary cholangitis (PBC)
|
NDA Filing |
NDA filing due 2017
|
| RVNC |
$26.50
+0.65 (+2.5%)
|
RT002 - SAKURA 2
Moderate to severe glabellar (frown) lines
|
Phase 2 |
Phase 3 completion of enrollment announced March 8, 2017. Data due 4Q 2017.
|
| RVNC |
$26.50
+0.65 (+2.5%)
|
RT002
Plantar fasciitis
|
Phase 2 |
Phase 2 data due 4Q 2017.
|
| RVNC |
$26.50
+0.65 (+2.5%)
|
RT002 - SAKURA 1
Moderate to severe glabellar (frown) lines
|
Phase 3 |
Phase 3 completion of enrollment announced March 8, 2017. Data due 4Q 2017.
|
| RXDX |
$10.35
+0.35 (+3.5%)
|
RXDX-105
Solid tumors - cancer
|
Phase 1b |
Phase 1b data update 2H 2017.
|
| RXII |
$0.64
+0.04 (+7.44%)
|
RXI-109-1402
Connective tissue growth factor (CTGF)
|
Phase 2 |
Phase 2 final readout due 2H 2017.
|
| RXII |
$0.64
+0.04 (+7.44%)
|
Samcyprone - RXI-SCP-1502
Cutaneous warts
|
Phase 2 |
Phase 2 early read outs due 2H 2017.
|
| SAGE |
$84.94
+1.63 (+1.96%)
|
Brexanolone - SAGE-547 (202C)
Postpartum Depression - moderate
|
Phase 3 |
Phase 2 data due 2H 2017.
|
| SAGE |
$84.94
+1.63 (+1.96%)
|
SAGE-217
Parkinson’s disease (PD)
|
Phase 2 |
Phase 2 initiation announced December 13, 2016. Data from Part A data released May 9, 2017. Part B data due 2H 2017.
|
| SAGE |
$84.94
+1.63 (+1.96%)
|
SAGE-217
Postpartum depression (PPD)
|
Phase 2 |
Phase 2 initiation 4Q 2016. Data due 2H 2017.
|
| SAGE |
$84.94
+1.63 (+1.96%)
|
Brexanolone - SAGE-547 (202B)
Postpartum Depression (Severe)
|
Phase 3 |
Phase 3 data due 2H 2017.
|
| SAGE |
$84.94
+1.63 (+1.96%)
|
SAGE-217
Essential tremor
|
Phase 2 |
Announced that screening has opened for Phase 2a trial - December 13, 2016. Data due 2H 2017.
|
| SBPH |
$13.00
-0.76 (-5.52%)
|
SB 9200
Hepatitis B (HBV)
|
Phase 2a |
Phase 2a initial data released May 23, 2017. Second cohort enrolling with top-line results due 4Q 2017.
|
| SGEN |
$63.25
-0.22 (-0.35%)
|
ADCETRIS in combination with chemotherapy ECHELON-1
Frontline Hodgkin lymphoma
|
Phase 3 |
Phase 3 data due in 2017.
|
| SNDX |
$13.24
-0.06 (-0.45%)
|
E2112
HR+, HER2- breast cancer
|
Phase 3 |
Phase 3 PFS data due by the end of 2017.
|
| SNGX |
$2.10
-0.05 (-2.33%)
|
SGX301 (synthetic hypericin)
Cutaneous T-Cell Lymphoma (CTCL) cancer
|
Phase 3 |
Phase 3 data due 2H 2017.
|
| SNY |
$49.61
+1.01 (+2.08%)
|
Dupixent (dupilumab) - LIBERTY ASTHMA QUEST
Asthma
|
Phase 3 |
Phase 3 data due 4Q 2017.
|
| SPPI |
$7.38
+0.24 (+3.36%)
|
Poziotinib
Breast cancer
|
Phase 2 |
Phase 2 initiated March 2016. Data due by the end of 2017.
|
| SVRA |
$6.41
+0.3 (+4.91%)
|
AIR001
Heart failure with preserved ejection fraction (HFpEF)
|
Phase 2 |
Phase 2 data due 4Q 2017.
|
| TBPH |
$42.56
+1.84 (+4.51%)
|
TD-9855
nOH
|
Phase 2a |
Phase 2a data due 2017.
|
| TCON |
$2.23
+0.07 (+3.48%)
|
TRC105 and Inlyta
Renal Cell Carcinoma (RCC) - cancer
|
Phase 2 |
Phase 2 initiated Dec 2014. Phase 2 data top-line PFS data due 2H 2017.
|
| TCON |
$2.23
+0.07 (+3.48%)
|
TRC105
Gestational Trophoblastic Neoplasia cancer
|
Phase 2 |
Phase 2 planned for 2016. Data due 4Q 2017.
|
| TCON |
$2.23
+0.07 (+3.48%)
|
TRC102
Mesothelioma cancer
|
Phase 2 |
Phase 2 initiated October 2015. Data are due in 2017.
|
| TSRO |
$149.77
+7.64 (+5.38%)
|
Niraparib - AVANOVA | Phase 1/2 |
Phase 1/2 data due 2H 2017.
|
| TSRO |
$149.77
+7.64 (+5.38%)
|
Niraparib and Keytruda (TOPACIO)
Triple-negative Breast Cancer or Ovarian Cancer
|
Phase 1/2 |
Phase 1/2 enrolling. Initial data presented at ASCO investor event. ORR 4/13 patients. Further data due 2H 2017.
|
| TSRO |
$149.77
+7.64 (+5.38%)
|
Niraparib - (QUADRA trial)
Cancer - ovarian
|
Phase 2 |
Phase 2 data due 2H 2017.
|
| VKTX |
$1.04
+0.06 (+6.04%)
|
VK2809
Hypercholesterolemia
|
Phase 2 |
Phase 2 data due 4Q 2017.
|
| VNDA |
$16.10
+0.3 (+1.9%)
|
Tradipitant
Gastroparesis
|
Phase 2 |
Phase 2 data due 4Q 2017.
|
| VNDA |
$16.10
+0.3 (+1.9%)
|
HETLIOZ (tasimelteon)
Jet Lag Disorder
|
Phase 2 |
Phase 2 data due in 2H 2017.
|
| VRNA |
$11.52
-0.21 (-1.79%)
|
RPL554
Maintenance treatment of COPD
|
Phase 2a |
Phase 2a data due 4Q 2017. Phase 2b trial planned for 2H 2017 with data due 2H 2018.
|
| VRTX |
$135.53
+0.7 (+0.52%)
|
VX-440 in combination with tezacaftor and ivacaftor
Cystic fibrosis who have one F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
|
Phase 2 |
Phase 2 data due 2H 2017.
|
| VRTX |
$135.53
+0.7 (+0.52%)
|
VX-152 in combination with tezacaftor and ivacaftor
Cystic fibrosis who have one F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
|
Phase 2 |
Phase 2 data due 2H 2017
|
| XBIT |
$5.38
+0.9 (+20.09%)
|
Xilonix
Pyoderma Gangrenosum
|
Phase 2 |
Noted November 2016 that Phase 2 trial has been completed and data is being finalized. Noted mid-March 2017 that data will be available soon. No definitive timeline given. Assume some time in 2017.
|
| XLRN |
$33.95
+1.52 (+4.69%)
|
ACE-083
Facioscapulohumeral muscular dystrophy
|
Phase 2 |
Phase 2 dosing initiation announced December 22, 2016. Initial data due late 2017.
|
| XNCR |
$22.20
+0.02 (+0.09%)
|
XmAb5871
IgG4-Related Disease (IgG4-RD)
|
Phase 2 |
Phase 2 top-line data due in 2017.
|
| XENT |
$27.10
+0.45 (+1.69%)
|
RESOLVE steroid-releasing implant
Recurrent sinus obstruction
|
PDUFA |
PDUFA January 7, 2018.
|
| EIGR |
$7.10
+0.15 (+2.16%)
|
Ubenimex - LIBERTY
Pulmonary arterial hypertension (PAH)
|
Phase 2 |
Phase 2 initiated July 2016. Enrollment completion announced May 15, 2017 with data due 1Q 2018 at JPM Conference - January 8-11, 2018.
|
| SGYP |
$4.59
+0.07 (+1.55%)
|
Trulance (plecanatide)
Constipation-predominant irritable bowel syndrome (IBS-C)
|
PDUFA |
Phase 3 data from first and second trials met primary endpoints - December 9 and 22, 2016. PDUFA date January 24, 2018.
|
| PFE |
$34.06
+0.18 (+0.53%)
|
Sutent (Sunitinib)
Renal cell carcinoma (RCC)
|
PDUFA priority review |
PDUFA date January 2018 for sNDA announced May 31, 2017. Specific date not released. BPC estimate late January.
|
| PFE |
$34.06
+0.18 (+0.53%)
|
Talazoparib
BRCA-mutated breast cancer
|
Phase 3 |
Phase 3 data due January 2018.
|
| AMGN |
$173.82
+2.47 (+1.44%)
|
XGEVA
Multiple Myeloma
|
PDUFA |
sBLA filing announced April 4, 2017. Acceptance of filing announced June 19, 2017 - PDUFA February 3, 2018.
|
| AERI |
$55.05
+1.05 (+1.94%)
|
Rhopressa
Glaucoma
|
PDUFA |
PDUFA date February 28, 2018. Advisory Committee planned.
|
| CORI |
$7.53
+0.15 (+2.02%)
|
Corplex Donepezil
Alzheimer's disease
|
Phase 3 |
Pilot bioequivalence data due released May 11, 2017. Pivotal trial to commence fall of 2017 with preliminary data due February 2018.
|
| ACOR |
$18.65
-0.05 (-0.27%)
|
Tozadenant
Parkinson’s disease (PD)
|
Phase 3 |
Phase 3 data due 1Q 2018.
|
| AMAG |
$18.20
+0.45 (+2.54%)
|
Rekynda
Hypoactive sexual desire disorder (HSDD)
|
NDA Filing |
NDA filing due early 2018.
|
| ANTH |
$1.82
+0.02 (+1.11%)
|
Sollpura - RESULT
Exocrine pancreatic insufficiency
|
Phase 3 |
Phase 3 data due end of 2017 or early 2018.
|
| ARGS |
$0.42
-0.04 (-7.29%)
|
AGS-003 ADAPT Trial
Metastatic renal cell carcinoma (mRCC)
|
Phase 3 |
Phase 3 trial recommended be discontinued for futility - February 22, 2016. Noted April 18, 2017 that it intends to continue the trial to 290 events (analysis of overall survival) - late 2017 or early 2018.
|
| ARGX |
$20.01
-0.58 (-2.82%)
|
ARGX-113
Myasthenia gravis (MG)
|
Phase 2 |
Phase 2 data due 1Q 2018.
|
| AXSM |
$5.40
+0.15 (+2.86%)
|
AXS-05 STRIDE-1
Treatment resistant depression
|
Phase 3 |
Phase 3 initiated March 2016. Top-line data due 1Q 2018.
|
| AZN |
$35.36
+0.48 (+1.38%)
|
Brilinta (THEMIS)
Type 2 Diabetes
|
Phase 3 |
Phase 3 data due 1Q 2018.
|
| BHVN |
$25.46
-1.34 (-5%)
|
Rimegepant
Migraine
|
Phase 3 |
Phase 3 trials to be initiated 2H 2017 with top-line data due 1Q 2018.
|
| BHVN |
$25.46
-1.34 (-5%)
|
BHV-4157 Trigriluzole
Spinocerebellar Ataxia
|
Phase 2/3 |
Phase 2b/3 enrollment commenced December 2016. Phase 2 top-line data due 1Q 2018.
|
| CLBS |
$4.28
+0.1 (+2.39%)
|
CLBS03
Type 1 diabetes
|
Phase 2 |
Phase 2 enrollment of first cohort completed September 2016. Second cohort commenced enrollment October 2016. Interim analysis due late 2017 or early 2018.
|
| CLSD |
$8.81
+0.2 (+2.31%)
|
Suprachoroidal CLS-TA - PEACHTREE
Macular edema associated with non-infectious uveitis
|
Phase 3 |
Phase 3 data preliminary data due early 2018.
|
| EARS |
$0.65
+0.01 (+1.55%)
|
Keyzilen (AM-101) - TACTT3
Acute inner ear tinnitus
|
Phase 3 |
Phase 3 TACTT3 enrollment resumption announced January 26, 2017 with top-line results expected in early 2018.
|
| FGEN |
$32.35
+0.75 (+2.37%)
|
Pamrevlumab (FG-3019)
Pancreatic cancer
|
Phase 2 |
Phase 2 ongoing. Data due late 2017 or 1Q 2018.
|
| GEMP |
$11.30
-0.02 (-0.18%)
|
Gemcabene - INDIGO-1
Severe Hypertriglyceridemia (SHTG)
|
Phase 2b |
Phase 2b data due early 2018.
|
| IDRA |
$1.73
+0.02 (+1.17%)
|
IMO-2125
Cancer - melanoma
|
Phase 2 |
Phase 2 arm enrolling. Overall response data due 1Q 2018.
|
| KPTI |
$9.96
+0.46 (+4.84%)
|
Selinexor - STORM
Quadruple Refractory Multiple Myeloma
|
Phase 2 |
Phase 2 positive top-line data released September 6, 2016. Updated data at ASH 2016. Top-line data from expansion cohort due early 2018.
|
| MEIP |
$2.16
+0.03 (+1.41%)
|
Pracinostat in combination with Vidaza
High-risk Myelodysplastic Syndrome (MDS)
|
Phase 2 |
Phase 2 commencement of dosing announced June 14, 2017 - data from first stage due 1Q 2018.
|
| NBRV |
$10.50
+1.19 (+12.78%)
|
Lefamulin - LEAP 2
Moderate to severe Community Acquired Bacterial Pneumonia (CABP)
|
Phase 3 |
Phase 3 enrollment to be completed 4Q 2017, with data due 1Q 2018.
|
| OHRP |
$0.63
-0.01 (-1.35%)
|
OHR-102 (MAKO)
Neovascular (Wet) Age-related Macular Degeneration (AMD)
|
Phase 3 |
Phase 3 data due late 2017 or early 2018.
|
| PFE |
$34.06
+0.18 (+0.53%)
|
Tanezumab
Chronic low back pain
|
Phase 3 |
Phase 3 ongoing. Estimate data due late 2017 or early 2018 using clinicaltrials.gov data.
|
| PFE |
$34.06
+0.18 (+0.53%)
|
Tanezumab
Osteoarthritis
|
Phase 3 |
Phase 3 ongoing. Estimate data late 2017 or early 2018 using clinicaltrials.gov data.
|
| REGN |
$526.53
+4.51 (+0.86%)
|
Praluent (alirocumab) ODYSSEY OUTCOMES
Cardiovascular events
|
Phase 3 |
Phase 3 data due 1Q 2018.
|
| SBBP |
$5.50
+0.75 (+15.79%)
|
COR-003 (levoketoconazole) - SONICS
Endogenous Cushing’s syndrome
|
Phase 3 |
Phase 3 top-line data due 1Q 2018.
|
| SGMO |
$9.20
+1.05 (+12.88%)
|
SB-318
MPS Type 1
|
Phase 1/2 |
Phase 1/2 trial initiated early 2017 with data due late 2017 or early 2018.
|
| SGMO |
$9.20
+1.05 (+12.88%)
|
SB-FIX
Hemophilia B
|
Phase 1/2 |
Phase 1/2 data due late 2017 or early 2018.
|
| SGMO |
$9.20
+1.05 (+12.88%)
|
SB-913
MPS Type 2
|
Phase 1/2 |
Phase 1/2 trial initiated early 2017 with data due late 2017 or early 2018.
|
| SMMT |
$11.49
+0.41 (+3.66%)
|
Ezutromid
Duchenne muscular dystrophy
|
Phase 2 |
Phase 2 completion of enrollment announced May 15, 2017. 24-week data due 1Q 2018.
|
| SNY |
$49.61
+1.01 (+2.08%)
|
Praluent (alirocumab) ODYSSEY OUTCOMES
Cardiovascular events
|
Phase 3 |
Phase 3 data due 1Q 2018.
|
| SPHS |
$2.06
+0.01 (+0.49%)
|
Topsalysin (PRX302)
Localized low to intermediate risk prostate cancer
|
Phase 2 |
Phase 2b six-month biopsy data for all patients in 1Q 2018 with final biopsy data due 4Q 2018.
|
| TCON |
$2.23
+0.07 (+3.48%)
|
TRC105 and Nexavar
Hepatocellular carcinoma (HCC) - cancer
|
Phase 2 |
Phase 2 dosing initiated May 2016 with data due early 2018.
|
| VICL |
$2.48
+0.01 (+0.4%)
|
VCL-HB01 HSV-2 Therapeutic Vaccine
Genital Herpes in Adults
|
Phase 2 |
Phase 2 trial initiated September 2016. Enrollment completion announced April 19, 2017 with data due 2Q 2018.
|
| VICL |
$2.48
+0.01 (+0.4%)
|
ASP0113 Vaccine
Hematopoietic cell transplant recipients
|
Phase 3 |
Initiated Phase 3 Jun 2013. Enrollment due to be completed 3Q 2016. Topline data due 1Q 2018.
|
| VTVT |
$4.80
+0.07 (+1.48%)
|
Azeliragon - STEADFAST
Mild Alzheimer’s disease
|
Phase 3 |
Phase 3 initiated 2Q 2015. Part A enrollment completed September 2016. Part B enrollment completion announced June 1, 2017. Data from Part A due early 2018. Part B due late 2018
|
| RIGL |
$2.78
+0.07 (+2.58%)
|
Fostamatinib
Immune Thrombocytopenic Purpura (ITP)
|
PDUFA |
Phase 3 data from the first trial released August 30 2016. Primary endpoint met. Data from second trial did not meet the primary endpoint. PDUFA date April 17, 2018.
|
| SGEN |
$63.25
-0.22 (-0.35%)
|
ADCETRIS
Cancer - ALCANZA trial for relapsed CD30-positive cutaneous T-cell lymphoma
|
Phase 3 |
Phase 3 data released August 2016. sBLA filing announced June 20, 2017. Estimate PDUFA date April 20, 2018 based on 10 month review.
|
| ALDR |
$19.40
+0.4 (+2.11%)
|
ALD403 - PROMISE 2
Frequent episodic migraine
|
Phase 3 |
Phase 3 PROMISE 2 initiation announced November 28, 2016. Data due 1H 2018.
|
| ALKS |
$58.68
+1.02 (+1.77%)
|
ALKS 3831 - ENLIGHTEN-2
Schizophrenia
|
Phase 3 |
Pivotal trial initiated February 2016. Data due mid-2018.
|
| AMGN |
$173.82
+2.47 (+1.44%)
|
ABP 798
RITUXAN biosimilar - non-Hodgkin lymphoma
|
Phase 3 |
Phase 3 enrolling. Estimate data 1H 2018 using clinicaltrials.gov data.
|
| ANAB |
$24.05
+0.65 (+2.78%)
|
ANB020
Severe adult eosinophilic asthma
|
Phase 2a |
Phase 2a data due 1H 2018.
|
| AVIR |
$0.58
+0.1 (+20.83%)
|
BTA074 5% topical gel
Condyloma
|
Phase 2 |
Phase 2 enrollment to be completed 2H 2017 with data due 1H 2018.
|
| BMY |
$57.33
+1.26 (+2.25%)
|
CM-651 – Opdivo + Yervoy
First-line Head and Neck Cancer
|
Phase 3 |
Phase 3 data due 1H 2018.
|
| BMY |
$57.33
+1.26 (+2.25%)
|
CM-451 – Opdivo + Yervoy
First-line Small cell lung cancer (SCLC)
|
Phase 3 |
Phase 3 data due 1H 2018.
|
| BMY |
$57.33
+1.26 (+2.25%)
|
CM-331– Opdivo
Second-line Small cell lung cancer (SCLC)
|
Phase 3 |
Phase 3 data due 1H 2018.
|
| BMY |
$57.33
+1.26 (+2.25%)
|
CM-227 – Opdivo + Yervoy
First-line Non-small cell lung cancer (NSCLC)
|
Phase 3 |
Phase 3 data due 1H 2018.
|
| BMY |
$57.33
+1.26 (+2.25%)
|
CM-078 – Opdivo
Second-line Non-small cell lung cancer (NSCLC)
|
Phase 3 |
Phase 3 data due 1H 2018.
|
| BMY |
$57.33
+1.26 (+2.25%)
|
CM-548 - Opdivo+SOC
First-line Glioblastoma (GBM) cancer
|
Phase 2 |
Phase 2 data due 1H 2018.
|
| CNAT |
$4.96
-0.15 (-2.94%)
|
Emricasan
Liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT)
|
Phase 2b |
Phase 2b initiated May 2014. Topline data due 1H 2018.
|
| DERM |
$30.75
+0.34 (+1.12%)
|
Olumacostat glasaretil (DRM01)
Acne
|
Phase 3 |
Phase 3 trial initiation announced January 3, 2017. Data are due 1H 2018.
|
| EBIO |
$1.47
+0 (+0.34%)
|
Vicinium
Non-muscle invasive bladder cancer (NMIBC)
|
Phase 3 |
Phase 3 enrollment to be completed 2H 2017, with 3-month top-line data due 2Q 2018. DSMB recommended June 1, 2017 that the trial continue as planned.
|
| EIGR |
$7.10
+0.15 (+2.16%)
|
Ubenimex - ULTRA
Secondary lymphedema
|
Phase 2 |
Phase 2 dosing commenced July 2016. Enrollment to be completed 4Q 2017. Data due 2Q 2018.
|
| ESPR |
$42.31
+1.29 (+3.14%)
|
Bempedoic acid (ETC-1002-040)
Hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins
|
Phase 3 |
Phase 3 long-term safety and tolerability trial initiated January 2016. Completion of enrollment announced January 25, 2017. Top-line results due 2Q 2018.
|
| FBIO |
$4.82
+0.03 (+0.63%)
|
CEVA101
Severe Traumatic Brain Injury
|
Phase 2 |
Phase 2 data in children due 1H 2018.
|
| FBIO |
$4.82
+0.03 (+0.63%)
|
Pepvax vaccine
Cytomegalovirus (CMV)
|
Phase 2 |
Phase 2 data due 1H 2018.
|
| FLKS |
$4.45
-0.05 (-1.12%)
|
FLX-787
Amyotrophic lateral sclerosis (ALS)
|
Phase 2 |
Phase 2 initiated September 2016. Readout due 2017/18.
|
| GLMD |
$5.87
-0.41 (-6.53%)
|
Aramchol - ARREST
Non-Alcoholic Steatohepatitis (NASH)
|
Phase 2b |
Phase 2b enrollment complettion announced January 9, 2017. Data due 2Q 2018.
|
| IDRA |
$1.73
+0.02 (+1.17%)
|
IMO-8400
Dermatomyositis
|
Phase 2 |
Phase 2 initiated November 2015. Enrollment to be completed by the end of 2017 with data due 1H 2018.
|
| JNJ |
$136.05
+1.13 (+0.85%)
|
Esketamine
Treatment resistant depression
|
Phase 3 |
Phase 3 ongoing. Data and regulatory filings likely due 2018.
|
| KMPH |
$3.40
+0.05 (+1.49%)
|
KP415
ADHD
|
Phase 2 |
Phase 1 trial completed December 2016. Efficacy trials to commence 2H 2017, with data 1H 2018.
|
| KURA |
$7.90
+0.8 (+11.27%)
|
Tipifarnib
Chronic myelomonocytic leukemia (CMML) - cancer
|
Phase 2 |
Phase 2 first dosing announced January 17, 2016 with data due 1H 2018.
|
| MACK |
$1.46
+0.15 (+11.45%)
|
MM-141 - CARRIE
Cancer - front line pancreatic cancer
|
Phase 2 |
Phase 2 completion of enrollment announced June 19, 2017. Data due 1H 2018.
|
| MDWD |
$7.80
+0.15 (+1.96%)
|
NexoBrid
Severe burns
|
Phase 3 |
Phase 3 initiated mid April 2015. Data due 1H 2018.
|
| NVCR |
$17.35
-0.15 (-0.86%)
|
Tumor Treating Fields (TTFields) STELLAR
Mesothelioma
|
Phase 2 |
Phase 2 enrollment completion announced March 31, 2017. Data likely 2Q 2018.
|
| OBSV |
$6.66
+0.73 (+12.31%)
|
OBE001 - IMPLANT2
IVF
|
Phase 2 |
Phase 2 trial did not meet primary endpoint in 2016. Phase 3 European trial initiation announced March 7, 2017. Data due 1H 2018.
|
| OBSV |
$6.66
+0.73 (+12.31%)
|
OBE2109 - EDELWEISS
Endometriosis
|
Phase 2b |
Phase 2b data due 1H 2018.
|
| OCUL |
$11.54
+0.5 (+4.53%)
|
OTX-TP
Glaucoma and ocular hypertension
|
Phase 3 |
Phase 3 initiated October 2016. Data due 1H 2018.
|
| PRTA |
$56.99
+0.38 (+0.67%)
|
NEOD001 PRONTO
Previously-treated patients with AL amyloidosis and persistent cardiac dysfunction
|
Phase 2b |
Phase 2b data due 2Q 2018.
|
| RETA |
$29.26
+0.52 (+1.81%)
|
Bardoxolone methyl - CATALYST
Pulmonary arterial hypertension associated with connective tissue disease - CTD-PAH
|
Phase 3 |
Phase 3 commenced enrolment October 2016 with data due 1H 2018.
|
| RNN |
$3.01
+0.03 (+0.97%)
|
RX-3117 in combination with Abraxane
First-line pancreatic cancer
|
Phase 2a |
Phase 2 data due 2Q 2018.
|
| RXDX |
$10.35
+0.35 (+3.5%)
|
STARTRK-2 entrectinib
Solid tumors - cancer
|
Phase 2 |
Phase 2 trial initiated September 2015. Noted June 7, 2017 that enrollment will be completed 3Q 2017 with data due 1H 2018.
|
| SAGE |
$84.94
+1.63 (+1.96%)
|
SAGE-217
Major Depressive Disorder (MDD)
|
Phase 2 |
Phase 2 initiation announced December 19, 2016. Part B data due 1H 2018.
|
| TNXP |
$4.37
+0.11 (+2.58%)
|
TNX-102 SL
Post-traumatic stress disorder (PTSD)
|
Phase 3 |
Initiation of first of two Phase 3 trials announced March 28, 2017 in military-related PTSD 1Q 2017. Interim analysis due 1H 2018 with top-line data due 2H 2018.
|
| TOCA |
$14.59
-0.26 (-1.75%)
|
Toca 511 & Toca FC
Recurrent brain cancer
|
Phase 2/3 |
Data from Phase 2 portion are due 1H 2018.
|
| CELG |
$133.68
+0.85 (+0.64%)
|
Luspatercept - BELIEVE
b -thalassemia
|
Phase 3 |
Phase 3 enrollment completion announced June 1, 2017 with data due mid-2018.
|
| CELG |
$133.68
+0.85 (+0.64%)
|
Luspatercept - MEDALIST
Myelodysplastic syndromes (MDS) cancer
|
Phase 3 |
Phase 3 enrollment completion announced June 1, 2017 with data due mid-2018.
|
| ESPR |
$42.31
+1.29 (+3.14%)
|
Bempedoic acid - CLEAR LDL-C Lowering Program 1002-046, 1002-047 and 1002-048
Hypercholesterolemia - statin intolerance
|
Phase 3 |
Phase 3 initiation of efficacy trials announced January 8, 2017. Data due mid 2018.
|
| FOMX |
$4.51
+0.17 (+3.92%)
|
FMX103
Papulopustular rosacea
|
Phase 3 |
Phase 2 top-line data released September 12, 2016. Endpoints met. Phase 3 trial to be initiation announced June 12, 2017 with top-line data due mid-2018.
|
| GNMX |
$1.32
+1.32 (+-7.69%)
|
AEVI-001 (NFC-1)
ADHD - 9-Gene subset
|
Phase 2 |
Phase 2 trial to be initiated 2H 2017 with data due mid-2018.
|
| HSGX |
$1.79
+0.08 (+4.68%)
|
NeoCart
Cartilage defects in the knee
|
Phase 3 |
Phase 3 enrollment to be completed by end of 2Q 2017. Top-line data due mid 2018.
|
| KPTI |
$9.96
+0.46 (+4.84%)
|
Selinexor - SADAL
Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)
|
Phase 2b |
Phase 2b additional interim data released April 4, 2017 at AACR. Final top-line data due mid-2018.
|
| LLY |
$84.31
+1.67 (+2.02%)
|
Ramucirumab
Second-line bladder cancer
|
Phase 3 |
Phase 3 PFS data released May 31, 2017 - primary endpoint met. Final OS results are currently expected in mid-2018.
|
| RGLS |
$0.99
+0.04 (+4.3%)
|
RG-012 - HERA
Alport Syndrome
|
Phase 2 |
Phase 2 interim data due mid-2018.
|
| VTL |
$3.50
+0.05 (+1.45%)
|
VTI-308
Alcohol-induced liver decompensation, or AILD
|
Phase 3 |
Phase 3 VTI-208 trial failed. New VTI-308 trial initiated May 2016. Data due mid 2018.
|
| XLRN |
$33.95
+1.52 (+4.69%)
|
Luspatercept - MEDALIST
Myelodysplastic syndromes (MDS) cancer
|
Phase 3 |
Phase 3 enrollment completion announced June 1, 2017 with data due mid-2018.
|
| XLRN |
$33.95
+1.52 (+4.69%)
|
Luspatercept - BELIEVE
b -thalassemia
|
Phase 3 |
Phase 3 enrollment completion announced June 1, 2017 with data due mid-2018.
|
| AZN |
$35.36
+0.48 (+1.38%)
|
Bydureon
Type 2 Diabetes
|
Phase 3 |
Phase 3 Cardiovascular Outcome trial data due 3Q 2017.
|
| SBBP |
$5.50
+0.75 (+15.79%)
|
COR-003 (levoketoconazole) - LOGICS
Endogenous Cushing’s syndrome
|
Phase 3 |
Phase 3 enrollment from second trial to begin mid-2017 with top-line data expected in 3Q 2018.
|
| CNCE |
$14.63
+0.82 (+5.94%)
|
AVP-786
Agitation in patients with Alzheimer's disease
|
Phase 3 |
Phase 3 initiated December 2015. Trial to be completed 3Q 2018
|
| AGN |
$247.11
+2.72 (+1.11%)
|
Brazikumab
Crohn's disease
|
Phase 2b |
Phase 2b data due 2018.
|
| AGN |
$247.11
+2.72 (+1.11%)
|
Cariprazine
Major depressive disorder (MDD)
|
Phase 3 |
Phase 3 data due 2018.
|
| AGN |
$247.11
+2.72 (+1.11%)
|
ATOGEPANT
Prophylaxis (migraine)
|
Phase 2b |
Phase 2b top-line data due 2018.
|
| AGN |
$247.11
+2.72 (+1.11%)
|
UBROGEPANT
Acute (migraine)
|
Phase 3 |
Phase 3 initiated July 2016. Data due 2018.
|
| AGN |
$247.11
+2.72 (+1.11%)
|
ABICIPAR
Age-related macular degeneration (AMD)
|
Phase 3 |
Phase 3 data due 2018.
|
| ALDX |
$4.25
+0.05 (+1.19%)
|
ADX-102
Noninfectious anterior uveitis
|
Phase 3 |
Phase 3 trial initiation announced April 27, 2017 with data due 2H 2018.
|
| ALDX |
$4.25
+0.05 (+1.19%)
|
ADX-102
Sjögren-Larsson Syndrome (SLS)
|
Phase 2 |
Phase 3 trial initial data due 2H 2018.
|
| ANIK |
$47.87
+0.6 (+1.27%)
|
Cingal
Osteoarthritis
|
Phase 3 |
Additional Phase 3 trial commenced enrollment - May 25 2017. Trial to be completed in 2018.
|
| AQXP |
$14.67
-0.01 (-0.08%)
|
AQX-1125 LEADERSHIP
Bladder pain syndrome/interstitial cystitis (BPS/IC).
|
Phase 3 |
Phase 2 trial did not meet endpoints - June 2015 but positive secondary endpoint data - August 2015. Phase 3 trial commenced September 2016. Reported March 9, 2017 that enrollment has been slower than expected. Data now due 2018.
|
| ARGX |
$20.01
-0.58 (-2.82%)
|
ARGX-113
Immune thrombocytopenia (ITP)
|
Phase 2 |
Phase 2 data due 2H 2018.
|
| AZN |
$35.36
+0.48 (+1.38%)
|
Benralizumab
COPD
|
Phase 3 |
Phase 3 data due 2018.
|
| AZN |
$35.36
+0.48 (+1.38%)
|
Selumetinib - ASTRA
Thyroid cancer
|
Phase 3 |
Phase 3 data due 2018.
|
| AZN |
$35.36
+0.48 (+1.38%)
|
Roxadustat - ANDES
Anaemia
|
Phase 3 |
Phase 3 data due 2018.
|
| AZN |
$35.36
+0.48 (+1.38%)
|
PT010
Chronic obstructive pulmonary disease (COPD)
|
Phase 3 |
Phase 3 data due 2018.
|
| AZN |
$35.36
+0.48 (+1.38%)
|
Durvalumab +/- tremelimumab (NEPTUNE)
Lung cancer
|
Phase 3 |
Phase 3 data due 2018.
|
| AZN |
$35.36
+0.48 (+1.38%)
|
Durvalumab +/- tremelimumab (DANUBE)
Bladder cancer
|
Phase 3 |
Phase 3 data due 2018.
|
| AZN |
$35.36
+0.48 (+1.38%)
|
Durvalumab +/- tremelimumab (EAGLE)
Head & neck cancer
|
Phase 3 |
Phase 3 data due 2018.
|
| AZN |
$35.36
+0.48 (+1.38%)
|
Anifrolumab
Lupus
|
Phase 3 |
Phase 3 data due 2018.
|
| BIIB |
$280.57
+1.97 (+0.71%)
|
Raxatrigine - BIIB074 (Nav1.7 inhibitor)
Painful Lumbosacral Radiculopathy (PLSR)
|
Phase 2 |
Phase 2 initiated 2016. Data due in 2018.
|
| BLRX |
$0.87
+0 (+0.11%)
|
BL-8040
Consolidation treatment for AML cancer patients
|
Phase 2b |
Phase 2b initiated August 2015. Interim analysis due in 2018, with top-line results expected in 2019.
|
| BMY |
$57.33
+1.26 (+2.25%)
|
CM-602 – Opdivo + Elo + SOC
Myeloma
|
Phase 3 |
Phase 3 data due 2H 2018.
|
| BMY |
$57.33
+1.26 (+2.25%)
|
CM-238 – Opdivo (Adjuvant)
Melanoma
|
Phase 3 |
Phase 3 data due 2H 2018.
|
| CELG |
$133.68
+0.85 (+0.64%)
|
MM-007 OPTIMISMM
Multiple Myeloma - refractory
|
Phase 3 |
Phase 3 trial to complete enrollment 1H 2017. Data due 2018.
|
| CELG |
$133.68
+0.85 (+0.64%)
|
Ozanimod - TRUE NORTH
Ulcerative Colitis
|
Phase 3 |
Phase 3 enrolling. Data due 2018.
|
| CELG |
$133.68
+0.85 (+0.64%)
|
GED-0301 (CD-003)
Crohn’s disease
|
Phase 3 |
Phase 3 enrolling. Data due 2018.
|
| CELG |
$133.68
+0.85 (+0.64%)
|
GED-0301 (CD-002)
Crohn’s disease
|
Phase 3 |
Phase 3 enrolling. Data due 2018.
|
| CELG |
$133.68
+0.85 (+0.64%)
|
ABRAXANE - IMpower 131 ( I/O Combo)
Non-small cell lung cancer (NSCLC)
|
Phase 3 |
Phase 3 data due 2018.
|
| CELG |
$133.68
+0.85 (+0.64%)
|
ABRAXANE - IMpower 130 ( I/O Combo)
Non-small cell lung cancer (NSCLC)
|
Phase 3 |
Phase 3 data due 2018.
|
| CELG |
$133.68
+0.85 (+0.64%)
|
ABRAXANE - IMPassion ( I/O Combo)
Triple Negative Metastatic Breast Cancer
|
Phase 3 |
Phase 3 data due 2018.
|
| CFRX |
$1.20
+0 (+0%)
|
CF-301
Serious infections caused byStaph aureus including MRSA
|
Phase 2 |
Phase 2 initiation announced May 25, 2017 - data due 4Q 2018.
|
| CLSN |
$2.63
+0.21 (+8.68%)
|
ThermoDox - OPTIMA
Hepatocellular carcinoma - liver cancer
|
Phase 3 |
Failed to meet primary endpoint. New Phase 3 trial initiated, with enrollment to be completed early 2018 with first interim efficacy endpoint due 4Q 2018.
|
| CNAT |
$4.96
-0.15 (-2.94%)
|
Emricasan
NASH cirrhosis - ENCORE-PH trial
|
Phase 2 |
Phase 2b initiated November 2016. Data due 2018.
|
| EARS |
$0.65
+0.01 (+1.55%)
|
AM-111 ASSENT
Acute inner ear hearing loss
|
Phase 3 |
Phase 3 ASSENT data due 2H 2018.
|
| FBIO |
$4.82
+0.03 (+0.63%)
|
IV Tramadol
Post-operative Pain
|
Phase 3 |
Phase 3 to be initiated in 2017 with data due in 2018.
|
| GEMP |
$11.30
-0.02 (-0.18%)
|
Gemcabene - AZURE-1
Nonalcoholic steatohepatitis (NASH) / Nonalcoholic fatty liver disease (NAFLD)
|
Phase 2 |
Phase 2 trial to be initiated in 2H 2017 with data due 2H 2018.
|
| GSK |
$44.16
+0.54 (+1.24%)
|
Closed Triple - CAPTAIN
Asthma
|
Phase 3 |
Phase 3 study completion due 2018.
|
| IMGN |
$5.82
-0.2 (-3.32%)
|
Kadcyla (KATHERINE).
HER2-positive breast cancer - residual invasive disease
|
Phase 3 |
Phase 3 data due in 2018.
|
| INCY |
$135.63
+1.64 (+1.22%)
|
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
|
Phase 3 |
Phase 3 initiated June 2016. Initial data due 2018
|
| INVA |
$12.73
+0.25 (+2%)
|
Closed Triple
Asthma
|
Phase 3 |
Phase 3 study completion due 2018.
|
| JNJ |
$136.05
+1.13 (+0.85%)
|
STELARA (USTEKINUMAB)
Ulcerative colitis
|
Phase 3 |
Phase 3 trial to be completed in 2018.
|
| JNJ |
$136.05
+1.13 (+0.85%)
|
DARZALEX (Daratumumab)
Frontline multiple myeloma (non-transplant)
|
Phase 3 |
Phase 3 data likely due 2018.
|
| KITE |
$93.99
+0.45 (+0.48%)
|
KTE-C19 (ZUMA-2)
Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) - cancer
|
Phase 2 |
Phase 2 pivotal initiated November 2015. Data due 2018.
|
| KITE |
$93.99
+0.45 (+0.48%)
|
KTE-C19 (ZUMA-3)
Adult patients with r/r ALL - cancer
|
Phase 1/2 |
Phase 1 data released at ASCO June 5, 2017. Complete remission 73%. Phase 2 data due 2018.
|
| KITE |
$93.99
+0.45 (+0.48%)
|
KTE-C19 (ZUMA-4)
Pediatric and young adult patients with r/r ALL - cancer
|
Phase 1/2 |
Phase 2 data due 2018.
|
| LLY |
$84.31
+1.67 (+2.02%)
|
Ramucirumab - RAINFALL
First-line gastric cancer
|
Phase 3 |
Phase 3 initial PFS data met primary endpoint. OS data due 2018.
|
| MACK |
$1.46
+0.15 (+11.45%)
|
MM-121
Cancer - Heregulin Positive Non-Small Cell Lung Cancer
|
Phase 2 |
Phase 2 initiated mid Feb 2015. Data due in 2018.
|
| MBRX |
$1.01
-0.03 (-2.88%)
|
Annamycin
Acute myeloid leukemia (AML) - cancer
|
Phase 1/2 |
Phase 1/2 data due 2018.
|
| MRK |
$66.02
+0.56 (+0.86%)
|
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
|
Phase 3 |
Phase 3 initiated June 2016. Initial data due 2018.
|
| NVS |
$86.34
+3.78 (+4.58%)
|
QVM149
Asthma
|
Phase 3 |
Phase 3 data due 2018.
|
| NVS |
$86.34
+3.78 (+4.58%)
|
LEE011: MONALEESA-7
Breast cancer - (pre-menopausal)
|
Phase 3 |
Phase 3 data 2H 2017.
|
| NVS |
$86.34
+3.78 (+4.58%)
|
Entresto - PIONEER
In-hospital initiation vs. enalapril following ADHF (acute decompensated heart failure)
|
Phase 3 |
Phase 3 trial completion due 2018.
|
| NVS |
$86.34
+3.78 (+4.58%)
|
Entresto - TRANSITION
Pre- vs. postdischarge initiation following ADHF (acute decompensated heart failure)
|
Phase 3 |
Phase 3 trial completion due 2018.
|
| NVS |
$86.34
+3.78 (+4.58%)
|
Entresto - PARAGON
HF-pEF (heart failure with preserved ejection fraction)
|
Phase 3 |
Phase 3 interim analysis due 2018. Filing 2019.
|
| NVS |
$86.34
+3.78 (+4.58%)
|
AIN457 (Cosentyx)
Non-radiographic axial SpA
|
Phase 3 |
Phase 3 data due 2018.
|
| PFE |
$34.06
+0.18 (+0.53%)
|
Tanezumab
Cancer pain
|
Phase 3 |
Phase 3 ongoing. Estimate data due 2018 using clinicaltrials.gov data.
|
| PLX |
$0.82
+0.01 (+1.49%)
|
PRX-102
Fabry disease
|
Phase 3 |
Phase 3 dosing commenced October 2016. Enrollment to be completed 2H 2017 with data in 2018.
|
| RIGL |
$2.78
+0.07 (+2.58%)
|
Fostamatinib
IgA nephropathy
|
Phase 2 |
Phase 2 preliminary data released January 5, 2017. Enrollment of second cohort to be completed in 2017 with data due in 2018.
|
| SGEN |
$63.25
-0.22 (-0.35%)
|
ADCETRIS in combination with chemotherapy - ECHELON-2
Frontline CD30-positive mature T-cell lymphomas - cancer
|
Phase 3 |
Phase 3 enrollment completed November 2016. Data are due in 2018.
|
| SNGX |
$2.10
-0.05 (-2.33%)
|
SGX203
Pediatric Crohn’s Disease
|
Phase 3 |
Phase 3 initiation due 1H 2017 with data due 2H 2018 - pending funding.
|
| SVRA |
$6.41
+0.3 (+4.91%)
|
Molgradex
Autoimmune pulmonary alveolar proteinosis (PAP)
|
Phase 3 |
Phase 3 data due 4Q 2018.
|
| TBPH |
$42.56
+1.84 (+4.51%)
|
Closed Triple - CAPTAIN
Asthma
|
Phase 3 |
Phase 3 study completion due 2018.
|
| TBPH |
$42.56
+1.84 (+4.51%)
|
Telavancin
Bacteremia
|
Phase 3 |
Phase 3 data due 2018.
|
| VNDA |
$16.10
+0.3 (+1.9%)
|
HETLIOZ (tasimelteon)
Smith-Magenis Syndrome
|
Phase 3 |
Phase 3 initiated 4Q 2016. Data due 2018.
|
| AGN |
$247.11
+2.72 (+1.11%)
|
RAPASTINEL
Major depressive disorder (MDD)
|
Phase 3 |
Phase 3 initiated October 2016. Data due early 2019.
|
| PRTO |
$1.45
+0.15 (+11.54%)
|
Vonapanitase (PRT-201) PATENCY-2
Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF)
|
Phase 3 |
Phase 3 enrollment to be completed 1Q 2018. Data due 1Q 2019.
|
| XNCR |
$22.20
+0.02 (+0.09%)
|
XmAb5871
Systemic Lupus Erythematosus (SLE)
|
Phase 2 |
Phase 2 trial initiated March 2016. Initial data due 2018 or early 2019.
|
| ABBV |
$73.18
+1.84 (+2.58%)
|
ABBV-8E12
Progressive supranuclear palsy (PSP)
|
Phase 2 |
Phase 2 initiation announced January 25, 2017. Estimated Primary Completion Date: May 2019
|
| ATNM |
$1.23
+0.02 (+1.65%)
|
Iomab-B
Hematopoietic Stem Cells Transplantation
|
Phase 3 |
Phase 3 initiated June 2016. Enrollment to be completed by the end of 2018. Data due 2H 2019
|
| BMY |
$57.33
+1.26 (+2.25%)
|
CM-568 - Opdivo + Yervoy
First-line Non-small cell lung cancer (NSCLC)
|
Phase 2 |
Phase 2 data due 2H 2018 – 1H 2019.
|
| CNAT |
$4.96
-0.15 (-2.94%)
|
Emricasan
NASH fibrosis - ENCORE-NF trial
|
Phase 2 |
Phase 2 trial initiated January 2016. Data are due 1H 2019.
|
| FBIO |
$4.82
+0.03 (+0.63%)
|
CEVA101
Severe Traumatic Brain Injury
|
Phase 2 |
Phase 2 data in adults due 1H 2019.
|
| GBT |
$29.25
-1.5 (-4.88%)
|
GBT440 - HOPE
Sickle cell disease in adults
|
Phase 3 |
Announced January 18, 2017 that Phase 3 enrollment has commenced. Previous guidance is for top-line data due 1H 2019.
|
| ICPT |
$130.57
+2.17 (+1.69%)
|
Obeticholic acid (OCA) - REGENERATE
Adult nonalcoholic steatohepatitis (NASH) patients.
|
Phase 3 |
Phase 3 data due 1H 2019.
|
| AKBA |
$16.49
+0.65 (+4.09%)
|
Vadadustat - INNO2VATE
Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD)
|
Phase 3 |
Phase 3 initiated August 2016. NDA filing pending positive data due 2019. Estimate data release mid-2019.
|
| AKBA |
$16.49
+0.65 (+4.09%)
|
Vadadustat - PRO2TECT
Non-dialysis patients with anemia related to CKD (NDD-CKD)
|
Phase 3 |
Phase 3 initiated January 2016. NDA filing pending positive data due 2019. Estimate data release mid-2019.
|
| ABBV |
$73.18
+1.84 (+2.58%)
|
Venetoclax
Relapsed or refractory multiple myeloma
|
Phase 3 |
Phase 3 trial initiated July 2016. Data due 2019.
|
| AZN |
$35.36
+0.48 (+1.38%)
|
Dapagliflozin - DECLARE
Type-2 diabetes
|
Phase 3 |
Cardiovascular outcome data due 2019 at the latest.
|
| CELG |
$133.68
+0.85 (+0.64%)
|
REVLIMID - ROBUST
First-line ABC Diffuse large B-cell lymphoma (DLBCL)
|
Phase 3 |
Phase 3 data due 2019.
|
| CELG |
$133.68
+0.85 (+0.64%)
|
REVLIMID - MAGNIFY NHL-010
Untreated Activated B-Cell Diffuse large B-cell lymphoma (DLBCL)
|
Phase 3 |
Phase 3 data due 2019.
|
| CNAT |
$4.96
-0.15 (-2.94%)
|
Emricasan
NASH cirrhosis - ENCORE-LF trial
|
Phase 2b |
Phase 2b data due 2019.
|
| CRBP |
$5.95
+0 (+0%)
|
Anabasum (Resunab)
Systemic Sclerosis
|
Phase 3 |
Phase 2 data released November 14, 2016. Phase 3 trial to be initiated 4Q 2017 with data due end of 2019.
|
| FOLD |
$10.09
+0.15 (+1.51%)
|
Migalastat HCl monotherapy (012)
Fabry Disease
|
Phase 3 |
Additional trials required following feedback from FDA. Enrollment to commence 2017 with data due in 2019.
|
| IMGN |
$5.82
-0.2 (-3.32%)
|
Kadcyla (KAITLIN)
HER2-positive breast cancer - adjuvant use
|
Phase 3 |
Phase 3 data due in 2019.
|
| JNJ |
$136.05
+1.13 (+0.85%)
|
INVOKANA - CREDENCE
Diabetic Kidney Disease
|
Phase 3 |
Phase 3 data due 2019.
|
| JNJ |
$136.05
+1.13 (+0.85%)
|
DARZALEX (Daratumumab)
Frontline multiple myeloma (transplant)
|
Phase 3 |
Phase 3 data likely due 2019.
|
| KPTI |
$9.96
+0.46 (+4.84%)
|
Selinexor - BOSTON
Multiple myeloma
|
Phase 3 |
Phase 3 trial initiation announced June 7, 2017. Enrollment to be completed 2018 with data due 2019.
|
| LLY |
$84.31
+1.67 (+2.02%)
|
AZD3293
Early Alzheimer's disease
|
Phase 3 |
Phase 3 data due 2019.
|
| MRK |
$66.02
+0.56 (+0.86%)
|
MK-8931 (019) - Verubecestat
Mild-to-moderate Alzheimer's
|
Phase 3 |
Fully enrolled. Data due in 2019.
|
| NVS |
$86.34
+3.78 (+4.58%)
|
QAW039 (fevipiprant)
Asthma
|
Phase 3 |
Phase 3 data due 2019.
|
| NVS |
$86.34
+3.78 (+4.58%)
|
OMB157 (ofatumumab)
Relapsing multiple sclerosis
|
Phase 3 |
Phase 3 data due 2019.
|
| NVS |
$86.34
+3.78 (+4.58%)
|
Entresto - PARADISE
AMI (acute myocardial infarction)
|
Phase 3 |
Phase 3 trial completion due 2019. Filing 2020.
|
| ABBV |
$73.18
+1.84 (+2.58%)
|
ABBV-8E12
Alzheimer's disease
|
Phase 2 |
Phase 2 initiation announced January 25, 2017. Estimated Primary Completion Date: April 2020.
|
| OBSV |
$6.66
+0.73 (+12.31%)
|
OBE2109 - PRIMROSE
Uterine fibroids
|
Phase 3 |
Phase 3 trial to be initiated 1H 2017 with data due 1H 2020.
|
| CELG |
$133.68
+0.85 (+0.64%)
|
REVLIMID - MAGNIFY NHL-008
Relapsed or Refractory Indolent Lymphoma
|
Phase 3 |
Phase 3 data due 2020.
|
| KMDA |
$6.30
-1.2 (-16%)
|
Alpha-1 antitrypsin (AAT)
Graft Versus Host Disease (GvHD)
|
Phase 2/3 |
Announced November 2, 2016 that Phase 2/3 enrollment to start imminently with data due 2020.
|
| NVCR |
$17.35
-0.15 (-0.86%)
|
Tumor Treating Fields (TTFields) METIS
Brain Metastases Originating from Non-Small Cell Lung Cancer
|
Phase 3 |
Phase 3 enrollment commenced October 2016. Data due 2020.
|
| PFE |
$34.06
+0.18 (+0.53%)
|
XTANDI
Metastatic hormone sensitive prostate cancer
|
Phase 3 |
Phase 3 ongoing. Estimate data 2020 using clinicaltrials.gov data.
|
| PFE |
$34.06
+0.18 (+0.53%)
|
XTANDI (EMBARK)
Non-metastatic high risk hormone-sensitive prostate cancer
|
Phase 3 |
Phase 3 ongoing. Estimate data 1H 2021 using clinicaltrials.gov data.
|
| NVCR |
$17.35
-0.15 (-0.86%)
|
Tumor Treating Fields (TTFields) LUNAR
Non-small cell lung cancer (NSCLC)
|
Phase 3 |
Phase 3 commencement of enrollment announced February 15, 2017. Data due 2021.
|